| Year |
Citation |
Score |
| 2024 |
Solomon SD, McMurray JJV, Vaduganathan M, Claggett B, Jhund PS, Desai AS, Henderson AD, Lam CSP, Pitt B, Senni M, Shah SJ, Voors AA, Zannad F, Abidin IZ, Alcocer-Gamba MA, et al. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. The New England Journal of Medicine. PMID 39225278 DOI: 10.1056/NEJMoa2407107 |
0.343 |
|
| 2024 |
Lu H, Chatur S, Lee S, Inciardi RM, Abanda M, Mc Causland FR, Kalayci A, Taheri KK, Shah AM, Cikes M, Claggett BL, Prasad N, Lam CSP, O'Meara E, Wang X, et al. Relationship Between Cardiac Structure and Function With Renal Function Trajectory and Outcomes in Patients With Heart Failure: Insights From the PARAGON-HF Trial. Circulation. Heart Failure. e011942. PMID 39212045 DOI: 10.1161/CIRCHEARTFAILURE.124.011942 |
0.308 |
|
| 2024 |
Espersen C, Campbell RT, Claggett BL, Biering-Sørensen T, Platz E. Reply to: Instrumental outcome modifiers to be considered among patients with acute heart failure. International Journal of Cardiology. 412: 132310. PMID 38950787 DOI: 10.1016/j.ijcard.2024.132310 |
0.33 |
|
| 2024 |
Lassen MCH, Ostrominski JW, Claggett BL, Packer M, Zile M, Desai AS, Shah AM, Cikes M, Merkely B, Gori M, Wang X, Hegde SM, Pfeffer MA, Lefkowitz M, McMurray JJV, et al. Cardiovascular-kidney-metabolic overlap in heart failure with preserved ejection fraction: Cardiac structure and function, clinical outcomes, and response to sacubitril/valsartan in PARAGON-HF. European Journal of Heart Failure. PMID 38932589 DOI: 10.1002/ejhf.3304 |
0.34 |
|
| 2024 |
Patel-Murray NL, Zhang L, Claggett BL, Xu D, Serrano-Fernandez P, Healey M, Wandel S, Chen CW, Jacob J, Xu H, Turner GM, Chutkow W, Yates DP, O'Donnell CJ, Prescott MF, et al. Aptamer Proteomics for Biomarker Discovery in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Proteomic Substudy. Journal of the American Heart Association. e033544. PMID 38904251 DOI: 10.1161/JAHA.123.033544 |
0.342 |
|
| 2024 |
Ramonfaur D, Buckley LF, Arthur V, Yang Y, Claggett BL, Ndumele CE, Walker KA, Austin T, Odden MC, Floyd JS, Sanders-van Wijk S, Njoroge J, Kizer JR, Kitzman D, Konety SH, et al. High Throughput Plasma Proteomics and Risk of Heart Failure and Frailty in Late Life. Jama Cardiology. PMID 38809565 DOI: 10.1001/jamacardio.2024.1178 |
0.305 |
|
| 2024 |
Fudim M, Cyr DD, Ward JH, Hernandez AF, Lepage S, Morrow DA, Sharma K, Claggett BL, Starling RC, Velazquez EJ, Williamson KM, Desai AS, Zieroth S, Solomon SD, Braunwald E, et al. Association of Sacubitril/Valsartan versus Valsartan with Blood Pressure Changes, and Symptomatic Hypotension: The PARAGLIDE-HF Trial. Journal of Cardiac Failure. PMID 38802053 DOI: 10.1016/j.cardfail.2024.04.030 |
0.319 |
|
| 2024 |
Ostrominski JW, Claggett BL, Miao ZM, Mc Causland FR, Anand IS, Desai AS, Jhund PS, Lam CSP, Pfeffer MA, Pitt B, Zannad F, Zile MR, Bomfim Wirtz A, Lay-Flurrie J, Viswanathan P, et al. Cardiovascular-Kidney-Metabolic Overlap in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Trial-Level Analysis. Journal of the American College of Cardiology. PMID 38744407 DOI: 10.1016/j.jacc.2024.05.005 |
0.324 |
|
| 2024 |
Vaduganathan M, Claggett BL, Lam CSP, Pitt B, Senni M, Shah SJ, Voors AA, Zannad F, Desai AS, Jhund PS, Viswanathan P, Bomfim Wirtz A, Schloemer P, Lay-Flurrie J, McMurray JJV, et al. Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS-HF trial. European Journal of Heart Failure. PMID 38742248 DOI: 10.1002/ejhf.3253 |
0.339 |
|
| 2024 |
Ostrominski JW, Aggarwal R, Claggett BL, Kulac IJ, Desai AS, Jhund PS, Lam CSP, Pitt B, Senni M, Shah SJ, Voors AA, Zannad F, Lay-Flurrie J, Viswanathan P, McMurray JJV, et al. Generalizability of the Spectrum of Kidney Risk in the FINEARTS-HF Trial to US Adults with Heart Failure. Journal of Cardiac Failure. PMID 38740173 DOI: 10.1016/j.cardfail.2024.04.015 |
0.323 |
|
| 2024 |
Selvaraj S, Claggett B, Shah SH, Mentz RJ, Khouri MG, Manichaikul AW, Khan SS, Rich SS, Mosley TH, Levitan EB, Arora P, Goyal P, Haring B, Eaton CB, Cheng RK, et al. Cardiovascular Burden of the V142I Transthyretin Variant. Jama. PMID 38734952 DOI: 10.1001/jama.2024.4467 |
0.31 |
|
| 2024 |
Solomon SD, Ostrominski JW, Vaduganathan M, Claggett B, Jhund PS, Desai AS, Lam CSP, Pitt B, Senni M, Shah SJ, Voors AA, Zannad F, Abidin IZ, Alcocer-Gamba MA, Atherton JJ, et al. Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: The FINEARTS-HF trial. European Journal of Heart Failure. PMID 38733212 DOI: 10.1002/ejhf.3266 |
0.362 |
|
| 2024 |
Kondo T, Jhund PS, Gasparyan SB, Yang M, Claggett BL, McCausland FR, Tolomeo P, Vadagunathan M, Heerspink HJL, Solomon SD, McMurray JJV. A hierarchical kidney outcome using win statistics in patients with heart failure from the DAPA-HF and DELIVER trials. Nature Medicine. PMID 38710952 DOI: 10.1038/s41591-024-02941-8 |
0.335 |
|
| 2024 |
Pabón MA, Wang X, Lam CSP, O'Meara E, Vaduganathan M, Claggett BL, Foà A, Lu H, Langkilde AM, De Boer RA, Desai AS, Hernandez AF, Inzucchi SE, Jhund PS, Kosiborod MN, et al. Sex Differences in Heart Failure With Improved Ejection Fraction: The DELIVER Trial. Jacc. Heart Failure. PMID 38661586 DOI: 10.1016/j.jchf.2024.03.011 |
0.339 |
|
| 2024 |
Espersen C, Campbell RT, Claggett BL, Lewis EF, Docherty KF, Lee MMY, Lindner M, Brainin P, Biering-Sørensen T, Solomon SD, McMurray JJV, Platz E. Predictors of heart failure readmission and all-cause mortality in patients with acute heart failure. International Journal of Cardiology. 132036. PMID 38599465 DOI: 10.1016/j.ijcard.2024.132036 |
0.362 |
|
| 2024 |
Chatur S, Neuen BL, Claggett BL, Beldhuis IE, Mc Causland FR, Desai AS, Rouleau JL, Zile MR, Lefkowitz MP, Packer M, McMurray JJ, Solomon SD, Vaduganathan M. Effects of Sacubitril/Valsartan Across the Spectrum of Renal Impairment in Patients With Heart Failure. Journal of the American College of Cardiology. PMID 38588927 DOI: 10.1016/j.jacc.2024.03.392 |
0.303 |
|
| 2024 |
Matsumoto S, Yang M, Shen L, Henderson A, Claggett BL, Desai AS, Lefkowitz M, Rouleau JL, Vardeny O, Zile MR, Jhund PS, Vaduganathan M, Solomon SD, McMurray JJV. Effects of sacubitril/valsartan according to polypharmacy status in PARAGON-HF. European Journal of Heart Failure. PMID 38587090 DOI: 10.1002/ejhf.3223 |
0.315 |
|
| 2024 |
Butt JH, Jhund PS, Docherty KF, Claggett BL, Vaduganathan M, Bachus E, Hernandez AF, Lam CSP, Inzucchi SE, Martinez FA, de Boer RA, Kosiborod MN, Desai AS, Køber L, Ponikowski P, et al. Dapagliflozin and Timing of Prior Heart Failure Hospitalization: A Patient-Level Meta-Analysis of DAPA-HF and DELIVER. Jacc. Heart Failure. PMID 38573262 DOI: 10.1016/j.jchf.2024.01.018 |
0.358 |
|
| 2024 |
Foà A, Vaduganathan M, Claggett BL, Pabon MA, Lu H, Pfeffer MA, Packer M, Vardeny O, Rouleau JL, Lefkowitz M, Mentz RJ, Jhund PS, Desai AS, McMurray JJ, Solomon SD. Sacubitril/Valsartan-Related Hypotension in Patients with Heart Failure and Preserved or Mildly Reduced Ejection Fraction. Journal of the American College of Cardiology. PMID 38537919 DOI: 10.1016/j.jacc.2024.02.035 |
0.334 |
|
| 2024 |
McDowell K, Kondo T, Talebi A, Teh K, Bachus E, de Boer RA, Campbell RT, Claggett B, Desai AS, Docherty KF, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, et al. Prognostic Models for Mortality and Morbidity in Heart Failure With Preserved Ejection Fraction. Jama Cardiology. PMID 38536153 DOI: 10.1001/jamacardio.2024.0284 |
0.317 |
|
| 2024 |
Peikert A, Vaduganathan M, Claggett BL, Kulac IJ, Foà A, Desai AS, Jhund PS, Carberry J, Lam CSP, Kosiborod MN, Inzucchi SE, Martinez FA, de Boer RA, Hernandez AF, Shah SJ, et al. Dapagliflozin in patients with heart failure and previous myocardial infarction: A participant-level pooled analysis of DAPA-HF and DELIVER. European Journal of Heart Failure. PMID 38487939 DOI: 10.1002/ejhf.3184 |
0.349 |
|
| 2024 |
Bhatt AS, Vaduganathan M, Claggett BL, Kulac IJ, Anand IS, Desai AS, Fang JC, Hernandez AF, Jhund PS, Kosiborod MN, Sabatine MS, Shah SJ, Vardeny O, McMurray JJV, Solomon SD, et al. Cost Effectiveness of Dapagliflozin for Heart Failure Across the Spectrum of Ejection Fraction: An Economic Evaluation Based on Pooled, Individual Participant Data From the DELIVER and DAPA-HF Trials. Journal of the American Heart Association. e032279. PMID 38390793 DOI: 10.1161/JAHA.123.032279 |
0.313 |
|
| 2024 |
Cunningham JW, Claggett BL, Lopes RD, McMurray JJV, Perkovic V, Carroll K, Hiemstra T, Khavandi K, Lukas MA, Ranganathan P, Shannon J, van Adelsberg J, Singh AK, Solomon SD. Daprodustat and Heart Failure in CKD. Journal of the American Society of Nephrology : Jasn. PMID 38383961 DOI: 10.1681/ASN.0000000000000321 |
0.335 |
|
| 2024 |
Minamisawa M, Inciardi RM, Claggett B, Cikes M, Liu L, Prasad N, Biering-Sørensen T, Lam CSP, Shah SJ, Zile MR, O'Meara E, Redfield MM, McMurray JJV, Solomon SD, Shah AM. Clinical implications of subclinical left ventricular dysfunction in heart failure with preserved ejection fraction: The PARAGON-HF study. European Journal of Heart Failure. PMID 38369856 DOI: 10.1002/ejhf.3167 |
0.339 |
|
| 2024 |
Adamo M, Metra M, Claggett BL, Miao ZM, Diaz R, Felker GM, McMurray JJV, Solomon SD, Biering-Sørensen T, Divanji PH, Heitner SB, Kupfer S, Malik FI, Teerlink JR. Tricuspid Regurgitation and Clinical Outcomes in Heart Failure With Reduced Ejection Fraction. Jacc. Heart Failure. PMID 38300212 DOI: 10.1016/j.jchf.2023.11.018 |
0.373 |
|
| 2024 |
Vardeny O, Desai AS, Jhund PS, Fang JC, Claggett B, de Boer RA, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez FA, Shah SJ, Mc Causland FR, Petrie MC, Vaduganathan M, et al. Dapagliflozin and Mode of Death in Heart Failure With Improved Ejection Fraction: A Post Hoc Analysis of the DELIVER Trial. Jama Cardiology. PMID 38265835 DOI: 10.1001/jamacardio.2023.5318 |
0.341 |
|
| 2024 |
Felker GM, Solomon SD, Metra M, Mcmurray JJV, Diaz R, Claggett B, Lanfear DE, Vandekerckhove H, Biering-Sørensen T, Lopes RD, Arias-Mendoza A, Momomura SI, Corbalan R, Ramires FJA, Zannad F, et al. Cardiac Troponin and Treatment Effects of Omecamtiv Mecarbil: Results From the GALACTIC-HF Study. Journal of Cardiac Failure. PMID 38215932 DOI: 10.1016/j.cardfail.2023.11.021 |
0.365 |
|
| 2023 |
Wang X, Lam CSP, Vaduganathan M, Kondo T, Yang M, Han Y, Pham VN, Chiang CE, Kitakaze M, Miao ZM, Jhund PS, Desai AS, Inzucchi SE, de Boer RA, Martinez FA, ... ... Claggett B, et al. Effects of Dapagliflozin in Patients in Asia: A Post Hoc Subgroup Analysis From the DELIVER Trial. Jacc. Asia. 4: 108-118. PMID 38371292 DOI: 10.1016/j.jacasi.2023.10.005 |
0.351 |
|
| 2023 |
Kondo T, Gasparyan SB, Jhund PS, Bengtsson O, Claggett BL, de Boer RA, Hernandez AF, Inzucchi SE, Kosiborod MN, Køber L, Lam CSP, Langkilde AM, Martinez FA, Petersson M, Ponikowski P, et al. Use of Win Statistics to Analyze Outcomes in the DAPA-HF and DELIVER Trials. Nejm Evidence. 2: EVIDoa2300042. PMID 38320525 DOI: 10.1056/EVIDoa2300042 |
0.331 |
|
| 2023 |
Mc Causland FR, Claggett BL, Vaduganathan M, Desai A, Jhund P, Vardeny O, Fang JC, de Boer RA, Docherty KF, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Saraiva JFK, et al. Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial. Jama Cardiology. PMID 37952176 DOI: 10.1001/jamacardio.2023.4664 |
0.311 |
|
| 2023 |
Kondo T, Butt JH, Curtain JP, Jhund PS, Docherty KF, Claggett BL, Vaduganathan M, Bachus E, Hernandez AF, Lam CSP, Inzucchi SE, Martinez FA, de Boer RA, Kosiborod MN, Desai AS, et al. Efficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVER. Circulation. Heart Failure. e010898. PMID 37886880 DOI: 10.1161/CIRCHEARTFAILURE.123.010898 |
0.379 |
|
| 2023 |
Pabon M, Cunningham J, Claggett B, Felker GM, McMurray JJV, Metra M, Diaz R, Wang X, Arias-Mendoza A, Bonderman D, Crespo-Leiro M, Fonseca C, Goncalvesova E, Lund M, O'Meara E, et al. Sex Differences in Heart Failure With Reduced Ejection Fraction in the GALACTIC-HF Trial. Jacc. Heart Failure. PMID 37831045 DOI: 10.1016/j.jchf.2023.07.029 |
0.317 |
|
| 2023 |
Ostrominski JW, Vaduganathan M, Selvaraj S, Claggett BL, Miao ZM, Desai AS, Jhund PS, Kosiborod MN, Lam CSP, Inzucchi SE, Martinez FA, de Boer RA, Hernandez AF, Shah SJ, Petersson M, et al. Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial. Circulation. PMID 37830208 DOI: 10.1161/CIRCULATIONAHA.123.065254 |
0.368 |
|
| 2023 |
Bhatt AS, Kosiborod MN, Claggett BL, Miao ZM, Vaduganathan M, Lam CSP, Hernandez AF, Martinez FA, Inzucchi SE, Shah SJ, de Boer RA, Jhund PS, Desai AS, Fang JC, Han Y, et al. Impact of COVID-19 in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction Enrolled in the DELIVER Trial. European Journal of Heart Failure. PMID 37771274 DOI: 10.1002/ejhf.3043 |
0.38 |
|
| 2023 |
Bhatt AS, Vaduganathan M, Claggett BL, Fonarow GC, Packer M, Pfeffer MA, Shah SJ, Shen X, Cristino J, McMurray JJV, Solomon SD, Gaziano TA. Health and Economic Evaluation of Sacubitril-Valsartan for Heart Failure Management. Jama Cardiology. PMID 37755814 DOI: 10.1001/jamacardio.2023.3216 |
0.304 |
|
| 2023 |
Docherty KF, McMurray JJV, Diaz R, Felker GM, Metra M, Solomon SD, Adams KF, Böhm M, Brinkley DM, Echeverria LE, Goudev AR, Howlett JG, Lund M, Ponikowski P, Yilmaz MB, ... ... Claggett BL, et al. The Effect of Omecamtiv Mecarbil in Hospitalized Patients as Compared with Outpatients with HFrEF: an Analysis of GALACTIC-HF. Journal of Cardiac Failure. PMID 37683911 DOI: 10.1016/j.cardfail.2023.08.020 |
0.388 |
|
| 2023 |
Chatur S, Vaduganathan M, Claggett BL, Mc Causland FR, Desai AS, Jhund PS, de Boer RA, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez FA, Shah SJ, Sabatine MS, Kober L, et al. Dapagliflozin in Patients with Heart Failure and Deterioration in Estimated Glomerular Filtration Rate to <25ml/min/1.73m. Journal of the American College of Cardiology. PMID 37634707 DOI: 10.1016/j.jacc.2023.08.026 |
0.302 |
|
| 2023 |
Pabon M, Claggett BL, Wang X, Miao ZM, Chatur S, Bhatt AS, Vaduganathan M, Fang JC, Desai AS, Jhund P, Martinez F, de Boer RA, Kosiborod MN, Lam CSP, Shah SJ, et al. Influence of background medical therapy on efficacy and safety of dapagliflozin in patients with heart failure with improved ejection fraction in the DELIVER trial. European Journal of Heart Failure. PMID 37632711 DOI: 10.1002/ejhf.3001 |
0.324 |
|
| 2023 |
Chatur S, Vaduganathan M, Claggett BL, Cunningham JW, Docherty KF, Desai AS, Jhund PS, De Boer RA, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez FA, Shah SJ, Petersson M, et al. Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial. Circulation. PMID 37632455 DOI: 10.1161/CIRCULATIONAHA.123.066506 |
0.308 |
|
| 2023 |
Kondo T, Wang X, Yang M, Jhund PS, Claggett BL, Vaduganathan M, Hernandez AF, Lam CSP, Inzucchi SE, Martinez FA, de Boer RA, Kosiborod MN, Desai AS, Køber L, Ponikowski P, et al. Efficacy of Dapagliflozin According to Geographic Location of Patients With Heart Failure. Journal of the American College of Cardiology. 82: 1014-1026. PMID 37610398 DOI: 10.1016/j.jacc.2023.05.056 |
0.343 |
|
| 2023 |
Wang X, Jering KS, Cikes M, Tokmakova MP, Mehran R, Han Y, East C, Mody FV, Wang Y, Lewis EF, Claggett B, McMurray JJV, Granger CB, Pfeffer MA, Solomon SD. Sex Differences in Clinical Characteristics and Outcomes After Myocardial Infarction With Low Ejection Fraction: Insights From PARADISE-MI. Journal of the American Heart Association. e028942. PMID 37609931 DOI: 10.1161/JAHA.122.028942 |
0.305 |
|
| 2023 |
Modin D, Lassen MCH, Claggett B, Johansen ND, Keshtkar-Jahromi M, Skaarup KG, Nealon J, Udell JA, Vardeny O, Solomon SD, Gislason G, Biering-Sørensen T. Influenza vaccination and cardiovascular events in patients with ischaemic heart disease and heart failure: A meta-analysis. European Journal of Heart Failure. PMID 37370193 DOI: 10.1002/ejhf.2945 |
0.301 |
|
| 2023 |
Peikert A, Goyal P, Vaduganathan M, Claggett BL, Kulac IJ, Miao ZM, Vardeny O, Kosiborod MN, Desai AS, Jhund PS, Lam CSP, Inzucchi SE, Martinez FA, de Boer RA, Hernandez AF, et al. Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Polypharmacy Status. Jacc. Heart Failure. PMID 37294244 DOI: 10.1016/j.jchf.2023.05.014 |
0.312 |
|
| 2023 |
Ostrominski JW, Claggett BL, Packer M, Pfeffer MA, Lam CSP, Zile MR, Desai AS, Jhund PS, Lefkowitz M, McMurray JJV, Solomon SD, Vaduganathan M. Duration of Heart Failure with Preserved Ejection Fraction and Outcomes with Sacubitril/Valsartan: Insights from the PARAGON-HF Trial. Journal of Cardiac Failure. PMID 37220823 DOI: 10.1016/j.cardfail.2023.05.003 |
0.367 |
|
| 2023 |
Chatur S, Vaduganathan M, Claggett B, Vardeny O, Desai AS, Jhund PS, de Boer RA, Lam CSP, Kosiborod MN, Shah SJ, Martinez F, Inzucchi SE, Hernandez AF, Haddad T, Mitter SS, et al. Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial. European Heart Journal. PMID 37220093 DOI: 10.1093/eurheartj/ehad283 |
0.379 |
|
| 2023 |
Selvaraj S, Claggett BL, Quarta CC, Yu B, Inciardi RM, Buxbaum JN, Mosley TH, Shah AM, Dorbala S, Falk RH, Solomon SD. Age Dependency of Cardiovascular Outcomes With the Amyloidogenic pV142I Transthyretin Variant Among Black Individuals in the US. Jama Cardiology. PMID 37212191 DOI: 10.1001/jamacardio.2023.1525 |
0.305 |
|
| 2023 |
Chatur S, Cunningham JW, Vaduganathan M, Mc Causland FR, Claggett BL, Desai AS, Miao ZM, Jhund PS, de Boer RA, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez FA, Shah SJ, et al. Renal and Blood Pressure Effects of Dapagliflozin in Recently Hospitalized Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction: Insights from the DELIVER Trial. European Journal of Heart Failure. PMID 37212168 DOI: 10.1002/ejhf.2915 |
0.316 |
|
| 2023 |
Bhatt AS, Kosiborod MN, Vaduganathan M, Claggett BL, Miao ZM, Kulac IJ, Lam CSP, Hernandez AF, Martinez F, Inzucchi SE, Shah SJ, de Boer RA, Jhund PS, Desai AS, Petersson M, et al. Effect of Dapagliflozin on Health Status and Quality-of-Life Across the Spectrum of Ejection Fraction: Participant-Level Pooled Analysis from the DAPA-HF & DELIVER Trials. European Journal of Heart Failure. PMID 37211977 DOI: 10.1002/ejhf.2909 |
0.311 |
|
| 2023 |
Vaduganathan M, Mentz RJ, Claggett BL, Miao ZM, Kulac IJ, Ward JH, Hernandez AF, Morrow DA, Starling RC, Velazquez EJ, Williamson KM, Desai AS, Zieroth S, Lefkowitz M, McMurray JJV, et al. Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF. European Heart Journal. PMID 37210743 DOI: 10.1093/eurheartj/ehad344 |
0.354 |
|
| 2023 |
Peikert A, Chandra A, Kosiborod MN, Claggett BL, Desai AS, Jhund PS, Lam CSP, Inzucchi SE, Martinez FA, de Boer RA, Hernandez AF, Shah SJ, Janssens SP, Belohlávek J, Borleffs CJW, et al. Association of Dapagliflozin vs Placebo With Individual Kansas City Cardiomyopathy Questionnaire Components in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the DELIVER Trial. Jama Cardiology. PMID 37208998 DOI: 10.1001/jamacardio.2023.1342 |
0.368 |
|
| 2023 |
Jering KS, Claggett BL, Pfeffer MA, Granger CB, Køber L, Lewis EF, Maggioni AP, Mann DL, McMurray JJV, Prescott MF, Rouleau JL, Solomon SD, Steg PG, von Lewinski D, Braunwald E. Prognostic Importance of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) Following High-Risk Myocardial Infarction in the PARADISE-MI Trial. Circulation. Heart Failure. e010259. PMID 37125529 DOI: 10.1161/CIRCHEARTFAILURE.122.010259 |
0.312 |
|
| 2023 |
Jhund PS, Claggett BL, Talebi A, Butt JH, Gasparyan SB, Wei LJ, McCaw ZR, Wilderäng U, Bengtsson O, Desai AS, Petersson M, Langkilde AM, de Boer RA, Hernandez AF, Inzucchi SE, et al. Effect of Dapagliflozin on Total Heart Failure Events in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Trial. Jama Cardiology. PMID 37099283 DOI: 10.1001/jamacardio.2023.0711 |
0.588 |
|
| 2023 |
Buckley LF, Claggett BL, Matsushita K, McMahon GM, Skali H, Coresh J, Folsom AR, Konety SH, Wagenknecht LE, Mosley TH, Shah AM. Chronic Kidney Disease, Heart Failure, and Adverse Cardiac Remodeling in Older Adults: The ARIC Study. Jacc. Heart Failure. PMID 37052553 DOI: 10.1016/j.jchf.2023.01.029 |
0.333 |
|
| 2023 |
Biering-Sørensen T, Cikes M, Lassen MCH, Claggett B, Minamisawa M, Santos ABS, Pieske-Kraigher E, Shah AM, Zile MR, McMurray JJV, Solomon SD, Cheng S. Regional contributions to impaired myocardial mechanical function in heart failure with preserved ejection fraction. European Heart Journal. Cardiovascular Imaging. PMID 37039073 DOI: 10.1093/ehjci/jead062 |
0.328 |
|
| 2023 |
Vardeny O, Fang JC, Desai AS, Jhund PS, Claggett B, Vaduganathan M, de Boer RA, Hernandez AF, Lam CSP, Inzucchi SE, Martinez FA, Kosiborod MN, DeMets D, O'Meara E, Zieroth S, et al. Author Correction: Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial. Nature Medicine. PMID 36932245 DOI: 10.1038/s41591-023-02302-x |
0.336 |
|
| 2023 |
Vaduganathan M, Claggett BL, Jhund P, Miao ZM, de Boer RA, Lam CSP, Desai AS, Bengsston O, McMurray JJV, Solomon SD. Dapagliflozin and All-Cause Hospitalizations in Patients With Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology. 81: 1004-1006. PMID 36889870 DOI: 10.1016/j.jacc.2022.12.026 |
0.314 |
|
| 2023 |
Butt JH, Docherty KF, Claggett BL, Desai AS, Fang JC, Petersson M, Langkilde AM, de Boer RA, Cabrera Honorio JW, Hernandez AF, Inzucchi SE, Kosiborod MN, Køber L, Lam CSP, Martinez FA, et al. Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum. Jacc. Heart Failure. 11: 375-388. PMID 36881399 DOI: 10.1016/j.jchf.2022.11.014 |
0.3 |
|
| 2023 |
Lanfear DE, Njoroge JN, Adams KF, Anand I, Fang JC, Ramires F, Sliwa-Hahnle K, Badat A, Burgess L, Gorodeski EZ, Williams C, Diaz R, Felker GM, McMurray JJV, Metra M, ... ... Claggett BL, et al. Omecamtiv Mecarbil in Black Patients With Heart Failure and Reduced Ejection Fraction: Insights From GALACTIC-HF. Jacc. Heart Failure. PMID 36881396 DOI: 10.1016/j.jchf.2022.11.021 |
0.346 |
|
| 2023 |
Kondo T, Jering KS, Borleffs CJW, de Boer RA, Claggett BL, Desai AS, Dobreanu D, Inzucchi SE, Hernandez AF, Janssens SP, Jhund P, Kosiborod MN, Lam CSP, Langkilde AM, Martinez FA, et al. Patient Characteristics, Outcomes, and Effects of Dapagliflozin According to the Duration of Heart Failure: A Prespecified Analysis of the DELIVER Trial. Circulation. PMID 36876483 DOI: 10.1161/CIRCULATIONAHA.122.062918 |
0.382 |
|
| 2023 |
Butt JH, Docherty KF, Claggett BL, Desai AS, Petersson M, Langkilde AM, de Boer RA, Hernandez AF, Inzucchi SE, Kosiborod MN, Køber L, Lam CSP, Martinez FA, Ponikowski P, Sabatine MS, et al. Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid-Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout: A Patient-Level Pooled Meta-analysis of DAPA-HF and DELIVER. Jama Cardiology. PMID 36811901 DOI: 10.1001/jamacardio.2022.5608 |
0.332 |
|
| 2023 |
Wang X, Claggett BL, Tian L, Malachias MVB, Pfeffer MA, Wei LJ. Quantifying and Interpreting the Prediction Accuracy of Models for the Time of a Cardiovascular Event-Moving Beyond C Statistic: A Review. Jama Cardiology. PMID 36723915 DOI: 10.1001/jamacardio.2022.5279 |
0.434 |
|
| 2022 |
Claggett BL, McCaw ZR, Tian L, McMurray JJV, Jhund PS, Uno H, Pfeffer MA, Solomon SD, Wei LJ. Quantifying Treatment Effects in Trials with Multiple Event-Time Outcomes. Nejm Evidence. 1. PMID 37645407 DOI: 10.1056/evidoa2200047 |
0.461 |
|
| 2022 |
Vardeny O, Fang JC, Desai AS, Jhund PS, Claggett B, Vaduganathan M, de Boer RA, Hernandez AF, Lam CSP, Inzucchi SE, Martinez FA, Kosiborod MN, DeMets D, O'Meara E, Zieroth S, et al. Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial. Nature Medicine. PMID 36522606 DOI: 10.1038/s41591-022-02102-9 |
0.394 |
|
| 2022 |
Rohde LE, Zimerman A, Vaduganathan M, Claggett BL, Packer M, Desai AS, Zile M, Rouleau J, Swedberg K, Lefkowitz M, Shi V, McMurray JJV, Solomon SD. Associations Between New York Heart Association Classification, Objective Measures, and Long-term Prognosis in Mild Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial. Jama Cardiology. PMID 36477809 DOI: 10.1001/jamacardio.2022.4427 |
0.347 |
|
| 2022 |
Inzucchi SE, Claggett BL, Vaduganathan M, Desai AS, Jhund PS, de Boer RA, Hernandez AF, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Verma S, Han Y, Kerr Saraiva JF, Bengtsson O, et al. Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial. The Lancet. Diabetes & Endocrinology. PMID 36372069 DOI: 10.1016/S2213-8587(22)00308-4 |
0.393 |
|
| 2022 |
Wang X, Vaduganathan M, Claggett BL, Hegde SM, Pabon M, Kulac IJ, Vardeny O, O'Meara E, Zieroth S, Katova T, McGrath MM, Pouleur AC, Jhund PS, Desai AS, Inzucchi SE, et al. Sex Differences in Characteristics, Outcomes and Treatment Response with Dapagliflozin across the Range of Ejection Fraction in Patients with Heart Failure: Insights from DAPA-HF and DELIVER. Circulation. PMID 36342789 DOI: 10.1161/CIRCULATIONAHA.122.062832 |
0.321 |
|
| 2022 |
Talha KM, Butler J, Greene SJ, Aggarwal R, Anker SD, Claggett BL, Solomon SD, McMurray JJV, Vaduganathan M, Fonarow GC. Population-Level Implications of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Preserved Ejection Fraction in the US. Jama Cardiology. PMID 36334258 DOI: 10.1001/jamacardio.2022.4348 |
0.362 |
|
| 2022 |
Mc Causland FR, Claggett BL, Vaduganathan M, Desai AS, Jhund P, de Boer RA, Docherty K, Fang J, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Saraiva JFK, McGrath MM, et al. Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Randomized Clinical Trial. Jama Cardiology. PMID 36326604 DOI: 10.1001/jamacardio.2022.4210 |
0.381 |
|
| 2022 |
Vaduganathan M, Claggett BL, Jhund P, de Boer RA, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, Hegde SM, Lindholm D, Petersson M, Langkilde AM, et al. Time to Clinical Benefit of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial. Jama Cardiology. PMID 36190011 DOI: 10.1001/jamacardio.2022.3750 |
0.39 |
|
| 2022 |
Desai AS, Jhund PS, Claggett BL, Vaduganathan M, Miao ZM, Kondo T, Barkoudah E, Brahimi A, Connolly E, Finn P, Lang NN, Mc Causland FR, McGrath M, Petrie MC, McMurray JJV, et al. Effect of Dapagliflozin on Cause-Specific Mortality in Patients With Heart Failure Across the Spectrum of Ejection Fraction: A Participant-Level Pooled Analysis of DAPA-HF and DELIVER. Jama Cardiology. PMID 36189985 DOI: 10.1001/jamacardio.2022.3736 |
0.363 |
|
| 2022 |
Chatur S, Claggett BL, Vardeny O, Jering K, Desai AS, Pfeffer MA, Lefkowitz M, McMurray JJ, Solomon SD, Vaduganathan M. Sacubitril/Valsartan and Loop Diuretic Requirement in Heart Failure with Preserved Ejection Fraction in the PARAGON-HF Trial. European Journal of Heart Failure. PMID 36181769 DOI: 10.1002/ejhf.2703 |
0.313 |
|
| 2022 |
Myhre PL, Vaduganathan M, Claggett BL, Miao ZM, Jhund PS, de Boer RA, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, Lindholm D, Petersson M, et al. Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. Jacc. Heart Failure. PMID 36114137 DOI: 10.1016/j.jchf.2022.08.007 |
0.353 |
|
| 2022 |
Zhao L, Zierath R, John JE, Claggett BL, Hall ME, Clark D, Butler KR, Correa A, Shah AM. Subclinical Risk Factors for Heart Failure With Preserved and Reduced Ejection Fraction Among Black Adults. Jama Network Open. 5: e2231878. PMID 36107422 DOI: 10.1001/jamanetworkopen.2022.31878 |
0.339 |
|
| 2022 |
Ostrominski JW, Vaduganathan M, Claggett BL, de Boer RA, Desai AS, Dobreanu D, Hernandez AF, Inzucchi SE, Jhund PS, Kosiborod M, Lam CSP, Langkilde AM, Lindholm D, Martinez FA, O'Meara E, et al. Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial. European Journal of Heart Failure. PMID 36054231 DOI: 10.1002/ejhf.2652 |
0.348 |
|
| 2022 |
Cunningham JW, Vaduganathan M, Claggett BL, Kulac IJ, Desai AS, Jhund PS, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, McGrath MM, et al. Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction. Journal of the American College of Cardiology. PMID 36041912 DOI: 10.1016/j.jacc.2022.07.021 |
0.328 |
|
| 2022 |
Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, McMurray JJV, Solomon SD. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet (London, England). PMID 36041474 DOI: 10.1016/S0140-6736(22)01429-5 |
0.374 |
|
| 2022 |
Jhund PS, Kondo T, Butt JH, Docherty KF, Claggett BL, Desai AS, Vaduganathan M, Gasparyan SB, Bengtsson O, Lindholm D, Petersson M, Langkilde AM, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nature Medicine. PMID 36030328 DOI: 10.1038/s41591-022-01971-4 |
0.376 |
|
| 2022 |
Butt JH, Jhund PS, Belohlávek J, de Boer RA, Chiang CE, Desai AS, Drożdzż J, Hernandez AF, Inzucchi SE, Katova T, Kitakaze M, Kosiborod MN, Lam CSP, Langkilde AM, Lindholm D, ... ... Claggett BL, et al. Efficacy and Safety of Dapagliflozin According to Frailty in Patients with Heart Failure: A Prespecified Analysis of the DELIVER Trial. Circulation. PMID 36029465 DOI: 10.1161/CIRCULATIONAHA.122.061754 |
0.306 |
|
| 2022 |
Zhang L, Cunningham JW, Claggett BL, Jacob J, Mendelson MM, Serrano-Fernandez P, Kaiser S, Yates DP, Healey M, Chen CW, Turner GM, Patel-Murray N, Zhao F, Beste MT, Laramie JM, et al. Aptamer Proteomics for Biomarker Discovery in Heart Failure with Reduced Ejection Fraction. Circulation. PMID 36029463 DOI: 10.1161/CIRCULATIONAHA.122.061481 |
0.315 |
|
| 2022 |
Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, Jhund PS, Belohlavek J, Chiang CE, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. The New England Journal of Medicine. PMID 36027570 DOI: 10.1056/NEJMoa2206286 |
0.356 |
|
| 2022 |
Huang B, Sun R, Claggett B, Tian L, Ludmir EB, Wei LJ. Handling Informative Premature Treatment or Study Discontinuation for Assessing Between-Group Differences in a Comparative Oncology Trial. Jama Oncology. PMID 35980612 DOI: 10.1001/jamaoncol.2022.2394 |
0.42 |
|
| 2022 |
Ramalho SHR, Claggett BL, Washko GR, Jose Estepar RS, Chang PP, Kitzman DW, Cipriano Junior G, Solomon SD, Skali H, Shah AM. Association of Pulmonary Function With Late-Life Cardiac Function and Heart Failure Risk: The ARIC Study. Journal of the American Heart Association. 11: e023990. PMID 35861819 DOI: 10.1161/JAHA.121.023990 |
0.306 |
|
| 2022 |
Wijkman MO, Claggett B, Vaduganathan M, Cunningham JW, Rørth R, Jackson A, Packer M, Zile M, Rouleau J, Swedberg K, Lefkowitz M, Shah SJ, Pfeffer MA, McMurray JJV, Solomon SD. Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials. Cardiovascular Diabetology. 21: 110. PMID 35717169 DOI: 10.1186/s12933-022-01545-1 |
0.322 |
|
| 2022 |
Metra M, Pagnesi M, Claggett BL, Díaz R, Felker GM, McMurray JJV, Solomon SD, Bonderman D, Fang JC, Fonseca C, Goncalvesova E, Howlett JG, Li J, O'Meara E, Miao ZM, et al. Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial. European Heart Journal. PMID 35675469 DOI: 10.1093/eurheartj/ehac293 |
0.363 |
|
| 2022 |
Cikes M, Planinc I, Claggett B, Cunningham J, Milicic D, Sweitzer N, Senni M, Gori M, Linssen G, Shah SJ, Packer M, Pfeffer M, Zile MR, Anand I, Chiang LM, et al. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. Jacc. Heart Failure. 10: 336-346. PMID 35483796 DOI: 10.1016/j.jchf.2022.01.018 |
0.355 |
|
| 2022 |
Solomon SD, Claggett BL, Miao ZM, Diaz R, Felker GM, McMurray JJV, Metra M, Corbalan R, Filippatos G, Goudev AR, Mareev V, Serpytis P, Suter T, Yilmaz MB, Zannad F, et al. Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial. European Heart Journal. PMID 35325102 DOI: 10.1093/eurheartj/ehac144 |
0.372 |
|
| 2022 |
Solomon SD, Vaduganathan M, Claggett BL, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Belohlavek J, Chiang CE, Willem Borleffs CJ, Comin-Colet J, et al. Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial. Jacc. Heart Failure. 10: 184-197. PMID 35241246 DOI: 10.1016/j.jchf.2021.11.006 |
0.354 |
|
| 2022 |
Chandra A, Skali H, Claggett B, Solomon SD, Rossi JS, Russell SD, Matsushita K, Kitzman DW, Konety SH, Mosley TH, Chang PP, Shah AM. Race- and Gender-Based Differences in Cardiac Structure and Function and Risk of Heart Failure. Journal of the American College of Cardiology. 79: 355-368. PMID 35086658 DOI: 10.1016/j.jacc.2021.11.024 |
0.324 |
|
| 2022 |
Pabón MA, Cunningham JW, Claggett BL, Packer M, Zile M, Pfeffer MA, Lefkowitz M, Shi V, Rizkala A, McMurray JJV, Solomon SD, Vaduganathan M. Natriuretic Peptide-Based Inclusion Criteria in Heart Failure with Preserved Ejection Fraction Clinical Trials: Insights from PARAGON-HF. European Journal of Heart Failure. PMID 35080787 DOI: 10.1002/ejhf.2439 |
0.306 |
|
| 2022 |
Mc Causland FR, Lefkowitz MP, Claggett B, Packer M, Senni M, Gori M, Jhund PS, McGrath MM, Rouleau JL, Shi V, Swedberg K, Vaduganathan M, Zannad F, Pfeffer MA, Zile M, et al. Angiotensin-neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure. European Journal of Heart Failure. PMID 34989105 DOI: 10.1002/ejhf.2421 |
0.319 |
|
| 2021 |
McCaw ZR, Claggett BL, Tian L, Solomon SD, Berwanger O, Pfeffer MA, Wei LJ. Practical Recommendations on Quantifying and Interpreting Treatment Effects in the Presence of Terminal Competing Risks: A Review. Jama Cardiology. PMID 34851356 DOI: 10.1001/jamacardio.2021.4932 |
0.472 |
|
| 2021 |
Desai AS, Vaduganathan M, Cleland JG, Claggett BL, Barkoudah E, Finn P, McCausland FR, Yilmaz MB, Lefkowitz M, Shi V, Pfeffer MA, McMurray JJV, Solomon SD. Mode of Death in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF Trial. Circulation. Heart Failure. CIRCHEARTFAILURE1210. PMID 34807713 DOI: 10.1161/CIRCHEARTFAILURE.121.008597 |
0.331 |
|
| 2021 |
Pfeffer MA, Claggett B, Lewis EF, Granger CB, Køber L, Maggioni AP, Mann D, McMurray JJV, Rouleau JL, Solomon SD, Steg PG, Berwanger O, Cikes M, De Pasquale CG, Fernandez A, et al. Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial. Circulation. PMID 34797725 DOI: 10.1161/CIRCULATIONAHA.121.057429 |
0.347 |
|
| 2021 |
Mooney L, Hawkins NM, Jhund PS, Redfield MM, Vaduganathan M, Desai AS, Rouleau JL, Minamisawa M, Shah AM, Lefkowitz MP, Zile MR, Van Veldhuisen DJ, Pfeffer MA, Anand IS, Maggioni AP, ... ... Claggett BL, et al. Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON-HF. Journal of the American Heart Association. e021494. PMID 34796742 DOI: 10.1161/JAHA.121.021494 |
0.377 |
|
| 2021 |
McCaw ZR, Tian L, Wei J, Claggett BL, Bretz F, Fitzmaurice G, Wei LJ. Choosing clinically interpretable summary measures and robust analytic procedures for quantifying the treatment difference in comparative clinical studies. Statistics in Medicine. 40: 6235-6242. PMID 34783094 DOI: 10.1002/sim.8971 |
0.416 |
|
| 2021 |
Ferreira JP, Rossignol P, Claggett BL, Solomon SD, Pitt B, Pfeffer M, Zannad F. Weight changes in heart failure with preserved ejection fraction: findings from TOPCAT. Clinical Research in Cardiology : Official Journal of the German Cardiac Society. PMID 34757487 DOI: 10.1007/s00392-021-01962-4 |
0.321 |
|
| 2021 |
Ferreira JP, Liu J, Claggett BL, Vardeny O, Pitt B, Pfeffer MA, Solomon SD, Zannad F. Outpatient diuretic intensification as endpoint in HFpEF trials: an analysis from TOPCAT. European Journal of Heart Failure. PMID 34755426 DOI: 10.1002/ejhf.2376 |
0.361 |
|
| 2021 |
Minamisawa M, Claggett B, Suzuki K, Hegde SM, Shah AM, Desai AS, Lewis EF, Shah SJ, Sweitzer NK, Fang JC, Anand IS, O'Meara E, Rouleau JL, Pitt B, Pfeffer MA, et al. Association of Hyper-Polypharmacy With Clinical Outcomes in Heart Failure With Preserved Ejection Fraction. Circulation. Heart Failure. CIRCHEARTFAILURE1200. PMID 34674539 DOI: 10.1161/CIRCHEARTFAILURE.120.008293 |
0.373 |
|
| 2021 |
Felker GM, Solomon SD, Claggett B, Diaz R, McMurray JJV, Metra M, Anand I, Crespo-Leiro MG, Dahlström U, Goncalvesova E, Howlett JG, MacDonald P, Parkhomenko A, Tomcsányi J, Abbasi SA, et al. Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure: A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical Trial. Jama Cardiology. PMID 34643642 DOI: 10.1001/jamacardio.2021.4027 |
0.355 |
|
| 2021 |
Shin SH, Claggett B, Inciardi RM, Santos ABS, Shah SJ, Zile MR, Pfeffer MA, Shah AM, Solomon SD. Prognostic Value of Minimal Left Atrial Volume in Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association. e019545. PMID 34325519 DOI: 10.1161/JAHA.120.019545 |
0.339 |
|
| 2021 |
Docherty KF, Jhund PS, Claggett B, Ferreira JP, Bengtsson O, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD, McMurray JJV, et al. Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial. Jama Cardiology. PMID 34319398 DOI: 10.1001/jamacardio.2021.2632 |
0.31 |
|
| 2021 |
Bhatt AS, Vaduganathan M, Claggett BL, Liu J, Packer M, Desai AS, Lefkowitz MP, Rouleau JL, Shi VC, Zile MR, Swedberg K, Vardeny O, McMurray JJV, Solomon SD. Effect of Sacubitril/Valsartan versus Enalapril on Changes in Heart Failure Therapies Over Time: The PARADIGM-HF Trial. European Journal of Heart Failure. PMID 34101308 DOI: 10.1002/ejhf.2259 |
0.326 |
|
| 2021 |
Solomon SD, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Lindholm D, Wilderäng U, Öhrn F, Claggett B, Langkilde AM, Petersson M, et al. Dapagliflozin in Heart Failure with Preserved and Mildly Reduced Ejection Fraction: Rationale and Design of the DELIVER Trial. European Journal of Heart Failure. PMID 34051124 DOI: 10.1002/ejhf.2249 |
0.339 |
|
| 2021 |
Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, Biering-Sørensen T, Böhm M, Bonderman D, Fang JC, Lanfear DE, Lund M, Momomura SI, O'Meara E, Ponikowski P, ... ... Claggett BL, et al. Effect of Ejection Fraction on Clinical Outcomes in Patients treated with Omecamtiv Mecarbil in GALACTIC-HF. Journal of the American College of Cardiology. PMID 34015475 DOI: 10.1016/j.jacc.2021.04.065 |
0.379 |
|
| 2021 |
Gori M, Claggett B, Senni M, Shah AM, Goldenberg I, Kutyifa V, Knappe D, Pouleur AC, Solomon SD. Combining diastolic dysfunction and natriuretic peptides to risk stratify patients with heart failure with reduced ejection fraction. International Journal of Cardiology. PMID 33887340 DOI: 10.1016/j.ijcard.2021.04.028 |
0.33 |
|
| 2021 |
Tromp J, Claggett BL, Liu J, Jackson AM, Jhund PS, Køber L, Widimský J, Boytsov SA, Chopra VK, Anand IS, Ge J, Chen CH, Maggioni AP, Martinez F, Packer M, et al. Global Differences in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. Circulation. Heart Failure. 14: e007901. PMID 33866828 DOI: 10.1161/CIRCHEARTFAILURE.120.007901 |
0.322 |
|
| 2021 |
Jering KS, Claggett B, Pfeffer MA, Granger C, Køber L, Lewis EF, Maggioni AP, Mann D, McMurray JJV, Rouleau JL, Solomon SD, Steg PG, van der Meer P, Wernsing M, Carter K, et al. Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics. European Journal of Heart Failure. PMID 33847047 DOI: 10.1002/ejhf.2191 |
0.35 |
|
| 2021 |
Vaduganathan M, Cunningham JW, Claggett BL, Causland FM, Barkoudah E, Finn P, Zannad F, Pfeffer MA, Rizkala AR, Sabarwal S, McMurray JJV, Solomon S, Desai AS. Worsening Heart Failure Episodes Outside a Hospital Setting in Heart Failure with Preserved Ejection Fraction: The PARAGON-HF Trial. Jacc. Heart Failure. PMID 33839075 DOI: 10.1016/j.jchf.2021.01.014 |
0.35 |
|
| 2021 |
Sørensen TB, Minamisawa M, Liu J, Claggett B, Papolos AI, Felker GM, McMurray JJV, Legg JC, Malik FI, Honarpour N, Kurtz CE, Teerlink JR, Solomon SD. The Effect of the Cardiac Myosin Activator, Omecamtiv Mecarbil, on Right Ventricular Structure and Function in Chronic Systolic Heart Failure (COSMIC -HF). European Journal of Heart Failure. PMID 33826209 DOI: 10.1002/ejhf.2181 |
0.3 |
|
| 2021 |
Reimer Jensen AM, Zierath R, Claggett B, Skali H, Solomon SD, Matsushita K, Konety S, Butler K, Kitzman DW, Biering-Sørensen T, Shah AM. Association of Left Ventricular Systolic Function With Incident Heart Failure in Late Life. Jama Cardiology. PMID 33729428 DOI: 10.1001/jamacardio.2021.0131 |
0.322 |
|
| 2021 |
Jering K, Claggett B, Redfield MM, Shah SJ, Anand IS, Martinez F, Sabarwal SV, Seferović PM, Kerr Saraiva JF, Katova T, Lefkowitz MP, Pfeffer MA, McMurray JJV, Solomon SD. Burden of Heart Failure Signs and Symptoms, Prognosis, and Response to Therapy: The PARAGON-HF Trial. Jacc. Heart Failure. PMID 33714741 DOI: 10.1016/j.jchf.2021.01.011 |
0.308 |
|
| 2021 |
Rohde LE, Claggett BL, Wolsk E, Packer M, Zile M, Swedberg K, Rouleau J, Pfeffer MA, Desai AS, Lund LH, Kober L, Anand I, Merkely B, Senni M, Shi V, et al. Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis. Circulation. Heart Failure. CIRCHEARTFAILURE1200. PMID 33706551 DOI: 10.1161/CIRCHEARTFAILURE.120.008052 |
0.31 |
|
| 2021 |
Beldhuis IE, Myhre PL, Bristow M, Claggett B, Damman K, Fang JC, Fleg JL, McKinlay S, Lewis EF, O'Meara E, Pitt B, Shah SJ, Vardeny O, Voors AA, Pfeffer MA, et al. Spironolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal Function. Journal of the American College of Cardiology. 77: 1211-1221. PMID 33663739 DOI: 10.1016/j.jacc.2020.12.057 |
0.347 |
|
| 2021 |
Mitchell GF, Solomon SD, Shah AM, Claggett BL, Fang JC, Izzo J, Abbas CA, Desai AS. Hemodynamic Effects of Sacubitril-Valsartan Versus Enalapril in Patients With Heart Failure in the EVALUATE-HF Study: Effect Modification by Left Ventricular Ejection Fraction and Sex. Circulation. Heart Failure. CIRCHEARTFAILURE1200. PMID 33663237 DOI: 10.1161/CIRCHEARTFAILURE.120.007891 |
0.348 |
|
| 2021 |
Ferreira JP, Claggett BL, Liu J, Desai AS, Pfeffer MA, Anand IS, Van Veldhuisen DJ, Kober L, Cleland JGF, Rouleau JL, Packer M, Zile MR, Shi VC, Lefkowitz MP, Shah SJ, et al. Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trial. European Journal of Heart Failure. PMID 33609066 DOI: 10.1002/ejhf.2134 |
0.345 |
|
| 2021 |
Bhatt AS, Jering KS, Vaduganathan M, Claggett BL, Cunningham JW, Rosenthal N, Signorovitch J, Thune JJ, Vardeny O, Solomon SD. Clinical Outcomes in Patients With Heart Failure Hospitalized With COVID-19. Jacc. Heart Failure. 9: 65-73. PMID 33384064 DOI: 10.1016/j.jchf.2020.11.003 |
0.59 |
|
| 2020 |
Suzuki K, Claggett B, Minamisawa M, Nochioka K, Mitchell GF, Anand IS, Zannad F, Shah SJ, Lefkowitz M, Shi V, Pfeffer MA, McMurray JJV, Solomon SD. Pulse Pressure, Prognosis, and Influence of Sacubitril/Valsartan in Heart Failure With Preserved Ejection Fraction. Hypertension (Dallas, Tex. : 1979). HYPERTENSIONAHA12016. PMID 33356401 DOI: 10.1161/HYPERTENSIONAHA.120.16277 |
0.334 |
|
| 2020 |
Piña IL, Camacho A, Ibrahim NE, Felker GM, Butler J, Maisel AS, Prescott MF, Williamson KM, Claggett BL, Desai AS, Solomon SD, Januzzi JL. Improvement of Health Status Following Initiation of Sacubitril/Valsartan in Heart Failure and Reduced Ejection Fraction. Jacc. Heart Failure. PMID 33189630 DOI: 10.1016/j.jchf.2020.09.012 |
0.319 |
|
| 2020 |
Rohde LE, Chatterjee NA, Vaduganathan M, Claggett B, Packer M, Desai AS, Zile M, Rouleau J, Swedberg K, Lefkowitz M, Shi V, McMurray JJV, Solomon SD. Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause: A PARADIGM-HF Analysis. Jacc. Heart Failure. PMID 32919916 DOI: 10.1016/J.Jchf.2020.06.015 |
0.402 |
|
| 2020 |
Chandra A, Alcala MAD, Claggett B, Desai AS, Fang JC, Heitner JF, Liu J, Pitt B, Solomon SD, Pfeffer MA, Lewis EF. Associations Between Depressive Symptoms and HFpEF-Related Outcomes. Jacc. Heart Failure. PMID 32919912 DOI: 10.1016/J.Jchf.2020.06.010 |
0.4 |
|
| 2020 |
Causland FRM, Lefkowitz MP, Claggett B, Anavekar NS, Senni M, Gori M, Jhund PS, McGrath MM, Packer M, Shi V, Veldhuisen DJv, Zannad F, Comin-Colet J, Pfeffer MA, McMurray JJV, et al. Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure with Preserved Ejection Fraction. Circulation. 142: 1236-1245. PMID 32845715 DOI: 10.1161/Circulationaha.120.047643 |
0.377 |
|
| 2020 |
Selvaraj S, Claggett BL, Pfeffer MA, Desai AS, McCausland FR, McGrath MM, Anand IS, van van Veldhuisen DJ, Kober L, Janssens S, Cleland JGF, Pieske B, Rouleau JL, Zile MR, Shi VC, et al. Serum Uric Acid, Influence of Sacubitril/Valsartan, and Cardiovascular Outcomes in Heart Failure with Preserved Ejection Fraction: PARAGON-HF. European Journal of Heart Failure. PMID 32840930 DOI: 10.1002/Ejhf.1984 |
0.428 |
|
| 2020 |
Cunningham JW, Vaduganathan M, Claggett BL, McMurray JJV, Solomon SD. Reply: The PARAGON-HF Trial: Toward Extension to Patients With HF Middle Range Ejection Fraction. Jacc. Heart Failure. 8: 698-699. PMID 32731952 DOI: 10.1016/J.Jchf.2020.06.005 |
0.388 |
|
| 2020 |
Cunningham JW, Claggett BL, O'Meara E, Prescott MF, Pfeffer MA, Shah SJ, Redfield MM, Zannad F, Chiang LM, Rizkala AR, Shi VC, Lefkowitz MP, Rouleau J, McMurray JJV, Solomon SD, et al. Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEF. Journal of the American College of Cardiology. 76: 503-514. PMID 32731928 DOI: 10.1016/J.Jacc.2020.05.072 |
0.367 |
|
| 2020 |
Solomon SD, Jhund PS, Claggett BL, Dewan P, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Inzucchi SE, Desai AS, Bengtsson O, Lindholm D, Sjostrand M, Langkilde AM, et al. Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial. Jacc. Heart Failure. PMID 32653447 DOI: 10.1016/J.Jchf.2020.04.008 |
0.467 |
|
| 2020 |
Cunningham JW, Vaduganathan M, Claggett BL, McMurray JJV, Solomon SD. Reply: NT-proBNP in Heart Failure With Preserved Ejection Fraction: Quest for a Marker Reflecting the Truth. Jacc. Heart Failure. 8: 597-598. PMID 32616172 DOI: 10.1016/J.Jchf.2020.05.002 |
0.394 |
|
| 2020 |
Teramoto K, Nadruz Junior W, Matsushita K, Claggett B, John JE, Skali H, Solomon S, Cheng S, Shah AM. Mid- to Late-Life Time-Averaged Cumulative Blood Pressure and Late-Life Cardiac Structure, Function, and Heart Failure. Hypertension (Dallas, Tex. : 1979). HYPERTENSIONAHA12014. PMID 32536273 DOI: 10.1161/Hypertensionaha.120.14833 |
0.42 |
|
| 2020 |
Selvaraj S, Myhre PL, Vaduganathan M, Claggett BL, Matsushita K, Kitzman DW, Borlaug BA, Shah AM, Solomon SD. Application of Diagnostic Algorithms for Heart Failure With Preserved Ejection Fraction to the Community. Jacc. Heart Failure. PMID 32535127 DOI: 10.1016/J.Jchf.2020.03.013 |
0.391 |
|
| 2020 |
Bhatt AS, Moscone A, McElrath EE, Varshney AS, Claggett BL, Bhatt DL, Januzzi JL, Butler J, Adler DS, Solomon SD, Vaduganathan M. Declines in Hospitalizations for Acute Cardiovascular Conditions During the COVID-19 Pandemic: A Multicenter Tertiary Care Experience. Journal of the American College of Cardiology. PMID 32470516 DOI: 10.1016/J.Jacc.2020.05.038 |
0.306 |
|
| 2020 |
Ferreira JP, Jhund PS, Duarte K, Claggett BL, Solomon SD, Pocock S, Petrie MC, Zannad F, McMurray JJV. Use of the Win Ratio in Cardiovascular Trials. Jacc. Heart Failure. 8: 441-450. PMID 32466836 DOI: 10.1016/J.Jchf.2020.02.010 |
0.31 |
|
| 2020 |
Vaduganathan M, Claggett BL, Jhund PS, Cunningham JW, Pedro Ferreira J, Zannad F, Packer M, Fonarow GC, McMurray JJV, Solomon SD. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet (London, England). PMID 32446323 DOI: 10.1016/S0140-6736(20)30748-0 |
0.394 |
|
| 2020 |
Suzuki K, Claggett B, Minamisawa M, Packer M, Zile MR, Rouleau J, Swedberg K, Lefkowitz M, Shi V, McMurray JJV, Zucker SD, Solomon SD. Liver function and prognosis, and influence of sacubitril/valsartan in patients with heart failure with reduced ejection fraction. European Journal of Heart Failure. 22: 1662-1671. PMID 32407608 DOI: 10.1002/Ejhf.1853 |
0.357 |
|
| 2020 |
Cunningham JW, Vaduganathan M, Claggett BL, John JE, Desai AS, Lewis EF, Zile MR, Carson P, Jhund PS, Kober L, Pitt B, Shah SJ, Swedberg K, Anand IS, Yusuf S, et al. Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical Trials. Jacc. Heart Failure. PMID 32387067 DOI: 10.1016/J.Jchf.2020.02.007 |
0.447 |
|
| 2020 |
Cunningham JW, Vaduganathan M, Claggett BL, Zile MR, Anand IS, Packer M, Zannad F, Lam CSP, Janssens S, Jhund PS, Kober L, Rouleau J, Shah SJ, Chopra VK, Shi VC, et al. Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction. Jacc. Heart Failure. PMID 32241619 DOI: 10.1016/J.Jchf.2020.03.002 |
0.329 |
|
| 2020 |
Vaduganathan M, Jhund PS, Claggett BL, Packer M, Widimský J, Seferovic P, Rizkala A, Lefkowitz M, Shi V, McMurray JJV, Solomon SD. A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction. European Heart Journal. PMID 32221596 DOI: 10.1093/Eurheartj/Ehaa184 |
0.444 |
|
| 2020 |
Vieira JL, Pfeffer M, Claggett BL, Stewart GC, Givertz MM, Coakley L, Mallidi HR, Mehra MR. The impact of statin therapy on neurological events following left ventricular assist system implantation in advanced heart failure. The Journal of Heart and Lung Transplantation : the Official Publication of the International Society For Heart Transplantation. PMID 32220561 DOI: 10.1016/J.Healun.2020.02.017 |
0.365 |
|
| 2020 |
Shin SH, Claggett B, Pfeffer MA, Skali H, Liu J, Aguilar D, Diaz R, Dickstein K, Gerstein HC, Køber LV, Lawson FC, Lewis EF, Maggioni AP, McMurray JJV, Probstfield JL, et al. Hyperglycaemia, ejection fraction and the risk of heart failure or cardiovascular death in patients with type 2 diabetes and a recent acute coronary syndrome. European Journal of Heart Failure. PMID 32212368 DOI: 10.1002/Ejhf.1790 |
0.446 |
|
| 2020 |
Selvaraj S, Claggett BL, Böhm M, Anker SD, Vaduganathan M, Zannad F, Pieske B, Lam CSP, Anand IS, Shi VC, Lefkowitz MP, McMurray JJV, Solomon SD. Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan. Journal of the American College of Cardiology. PMID 32192799 DOI: 10.1016/J.Jacc.2020.02.009 |
0.386 |
|
| 2020 |
Chandra A, Vaduganathan M, Lewis EF, Claggett B, McMurray JJV, Solomon SD. Reply: Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction. Jacc. Heart Failure. 8: 245-246. PMID 32131029 DOI: 10.1016/J.Jchf.2019.12.002 |
0.397 |
|
| 2020 |
Brainin P, Claggett B, Lewis EF, Dwyer KH, Merz AA, Silverman MB, Swamy V, Biering-Sørensen T, Rivero J, Cheng S, McMurray JJV, Solomon SD, Platz E. Body mass index and B-lines on lung ultrasonography in chronic and acute heart failure. Esc Heart Failure. PMID 32077268 DOI: 10.1002/Ehf2.12640 |
0.359 |
|
| 2020 |
Simpson J, Jhund PS, Lund LH, Padmanabhan S, Claggett BL, Shen L, Petrie MC, Abraham WT, Desai AS, Dickstein K, Køber L, Packer M, Rouleau JL, Mueller-Velten G, Solomon SD, et al. Prognostic Models Derived in PARADIGM-HF and Validated in ATMOSPHERE and the Swedish Heart Failure Registry to Predict Mortality and Morbidity in Chronic Heart Failure. Jama Cardiology. PMID 31995119 DOI: 10.1001/Jamacardio.2019.5850 |
0.453 |
|
| 2020 |
Murray EJ, Claggett BL, Granger B, Solomon SD, Hernán MA. Adherence-adjustment in placebo-controlled randomized trials: An application to the candesartan in heart failure randomized trial. Contemporary Clinical Trials. 90: 105937. PMID 31982649 DOI: 10.1016/J.Cct.2020.105937 |
0.343 |
|
| 2020 |
Lindner M, Thomas R, Claggett B, Lewis EF, Groarke J, Merz AA, Silverman MB, Swamy V, Rivero J, Hohenstein C, Solomon SD, McMurray JJ, Steigner ML, Platz E. Quantification of pleural effusions on thoracic ultrasound in acute heart failure. European Heart Journal. Acute Cardiovascular Care. 2048872620901835. PMID 31976745 DOI: 10.1177/2048872620901835 |
0.427 |
|
| 2020 |
Myhre PL, Vaduganathan M, O'Meara E, Claggett BL, de Denus S, Jarolim P, Anand IS, Pitt B, Rouleau JL, Solomon SD, Pfeffer MA, Desai AS. Mechanistic Effects of Spironolactone on Cardiovascular and Renal Biomarkers in Heart Failure With Preserved Ejection Fraction: A TOPCAT Biorepository Study. Circulation. Heart Failure. 13: e006638. PMID 31957468 DOI: 10.1161/Circheartfailure.119.006638 |
0.46 |
|
| 2020 |
Vaduganathan M, Claggett BL, Solomon SD. How Do SGLT-2 Inhibitors Work to Prevent Heart Failure? Jacc. Heart Failure. 8: 67-69. PMID 31896418 DOI: 10.1016/J.Jchf.2019.11.009 |
0.408 |
|
| 2020 |
Modin D, Claggett B, Gislason G, Hansen ML, Worck R, Johannessen A, Hansen J, Svendsen JH, Pallisgaard JL, Schou M, Køber L, Solomon SD, Torp-Pedersen C, Biering-Sørensen T. Catheter ablation for atrial fibrillation is associated with lower incidence of heart failure and death. Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups On Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology. 22: 74-83. PMID 31595294 DOI: 10.1093/Europace/Euz264 |
0.36 |
|
| 2020 |
Malachias MVB, Jhund P, Claggett B, Wijkman MO, Bentley-Lewis R, Brunel PC, Chaturvedi N, Desai AS, Haffner SM, Parving HD, Prescott MF, Solomon S, Zeeuw DD, Mcmurray JJ, Pfeffer MA. 2-OR: Impact of N Terminal Pro B-Type Natriuretic Peptide and High Sensitivity Cardiac Troponin on the Prediction of Death and Cardiovascular Events in High-Risk Patients with Type 2 Diabetes Diabetes. 69. DOI: 10.2337/Db20-2-Or |
0.319 |
|
| 2020 |
Wijkman MO, Claggett B, Diaz R, Gerstein HC, Kober L, Lewis E, Maggioni AP, Wolsk E, Aguilar D, Bentley-Lewis R, Mcmurray JJ, Probstfield JL, Riddle MC, Tardif J, Solomon S, et al. 1421-P: The Impact of Blood Pressure on Risk of Death Is Influenced by Prior Cardiovascular Disease in Patients with Type 2 Diabetes and a Recent Coronary Event Diabetes. 69. DOI: 10.2337/Db20-1421-P |
0.306 |
|
| 2020 |
Ramalho S, Claggett B, Kitzman D, Chang P, Cipriano Junior G, Solomon S, Skali H, Shah A. Differential impact of obstructive and restrictive ventilatory patterns on incident heart failure with preserved versus reduced ejection fraction in late-life European Heart Journal. 41. DOI: 10.1093/ehjci/ehaa946.3239 |
0.308 |
|
| 2020 |
Polanczyk CA, Claggett B, Packer M, Zile M, McMurray J, Rouleau JL, Swedberg K, Lefkowitz M, Shi V, Desai AS, Solomon SD, Lewis E. Impact Of Cardiovascular And Non-Cardiovascular Hospitalization On Quality Of Life In Patients With Heart Failure And Reduced Ejection Fraction Journal of the American College of Cardiology. 75: 1095. DOI: 10.1016/S0735-1097(20)31722-8 |
0.429 |
|
| 2020 |
Desai AS, Cleland J, Vaduganathan M, Claggett B, Barkoudah E, Finn PV, McCausland F, Yilmaz MB, Lefkowitz M, Shi V, Pfeffer MA, McMurray J, Solomon SD. Mode Of Death In Patients With Heart Failure And Left Ventricular Ejection Fraction≥45%: Insights From Paragon-Hf Journal of the American College of Cardiology. 75: 998. DOI: 10.1016/S0735-1097(20)31625-9 |
0.443 |
|
| 2020 |
Vardeny O, Claggett B, Anand I, Vaduganathan M, Pfeffer MA, Zannad F, Maggioni AP, Redfield MM, Packer M, Desai AS, Cleland J, Filippatos GS, Shah S, McMurray J, Solomon SD. Influence Of Age On Efficacy And Safety Of Sacubitril/Valsartan In Heart Failure With Preserved Ejection Fraction Journal of the American College of Cardiology. 75: 910. DOI: 10.1016/S0735-1097(20)31537-0 |
0.384 |
|
| 2020 |
Suzuki K, Claggett B, Minamisawa M, Packer M, Zile M, Rouleau JL, Swedberg K, Lefkowitz M, Shi V, McMurray J, Solomon SD. Liver Function And Prognosis, And Influence Of Sacubitril/Valsartan In Patients With Heart Failure With Reduced Ejection Fraction Journal of the American College of Cardiology. 75: 800. DOI: 10.1016/S0735-1097(20)31427-3 |
0.417 |
|
| 2020 |
Selvaraj S, Claggett B, Bohm M, Anker SD, Vaduganathan M, Shi V, Lefkowitz M, McMurray J, Solomon SD. Systolic Blood Pressure And Cardiovascular Outcomes In Heart Failure With Preserved Ejection Fraction: Paragon-Hf Journal of the American College of Cardiology. 75: 680. DOI: 10.1016/S0735-1097(20)31307-3 |
0.417 |
|
| 2019 |
Patel HC, Hayward C, Patel KS, Claggett B, Vazir A, Cowie MR. Impact on survival of combination inhalers in patients with COPD at high risk of cardiovascular events. International Journal of Cardiology. PMID 31813679 DOI: 10.1016/J.Ijcard.2019.11.138 |
0.304 |
|
| 2019 |
Shah AM, Cikes M, Prasad N, Li G, Getchevski S, Claggett B, Rizkala A, Lukashevich I, O'Meara E, Ryan JJ, Shah SJ, Mullens W, Zile MR, Lam CSP, McMurray JJV, et al. Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction. Journal of the American College of Cardiology. 74: 2858-2873. PMID 31806129 DOI: 10.1016/J.Jacc.2019.09.063 |
0.474 |
|
| 2019 |
Vardeny O, Claggett B, Vaduganathan M, Beldhuis I, Rouleau J, O'Meara E, Anand IS, Shah SJ, Sweitzer NK, Fang JC, Desai AS, Lewis EF, Pitt B, Pfeffer MA, Solomon SD, et al. Influence of Age on Efficacy and Safety of Spironolactone in Heart Failure. Jacc. Heart Failure. 7: 1022-1028. PMID 31779923 DOI: 10.1016/J.Jchf.2019.08.019 |
0.407 |
|
| 2019 |
Inciardi RM, Giugliano RP, Claggett B, Gupta DK, Chandra A, Ruff CT, Antman EM, Mercuri MF, Grosso MA, Braunwald E, Solomon SD. Left atrial structure and function and the risk of death or heart failure in atrial fibrillation. European Journal of Heart Failure. PMID 31777160 DOI: 10.1002/Ejhf.1606 |
0.416 |
|
| 2019 |
Solomon SD, Vaduganathan M, Claggett BL, Packer M, Zile M, Swedberg K, Rouleau J, Pfeffer MA, Desai A, Lund LH, Koeber L, Anand I, Sweitzer NK, Linssen G, Merkely B, et al. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure. Circulation. PMID 31736342 DOI: 10.1161/Circulationaha.119.044586 |
0.457 |
|
| 2019 |
McMurray JJV, Jackson AM, Lam CSP, Redfield MM, Anand IS, Ge J, Lefkowitz MP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Rizkala AR, Sabarwal SV, Shah AM, ... ... Claggett B, et al. Effects of Sacubitril-Valsartan, versus Valsartan, in Women Compared to Men with Heart Failure and Preserved Ejection Fraction: Insights from PARAGON-HF. Circulation. PMID 31736337 DOI: 10.1161/Circulationaha.119.044491 |
0.396 |
|
| 2019 |
Vaduganathan M, Claggett BL, Desai AS, Anker SD, Perrone SV, Janssens S, Milicic D, Arango JL, Packer M, Shi VC, Lefkowitz MP, McMurray JJV, Solomon SD. Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared with Valsartan in HFpEF. Journal of the American College of Cardiology. PMID 31726194 DOI: 10.1016/J.Jacc.2019.11.003 |
0.449 |
|
| 2019 |
Ramalho SHR, Claggett BL, Sweitzer NK, Fang JC, Shah SJ, Anand IS, Pitt B, Lewis EF, Pfeffer MA, Solomon SD, Shah AM. Impact of pulmonary disease on the prognosis in heart failure with preserved ejection fraction: the TOPCAT trial. European Journal of Heart Failure. PMID 31667977 DOI: 10.1002/Ejhf.1593 |
0.436 |
|
| 2019 |
Platz E, Campbell RT, Claggett B, Lewis EF, Groarke JD, Docherty KF, Lee MMY, Merz AA, Silverman M, Swamy V, Lindner M, Rivero J, Solomon SD, McMurray JJV. Lung Ultrasound in Acute Heart Failure: Prevalence of Pulmonary Congestion and Short- and Long-Term Outcomes. Jacc. Heart Failure. 7: 849-858. PMID 31582107 DOI: 10.1016/J.Jchf.2019.07.008 |
0.373 |
|
| 2019 |
Selvaraj S, Claggett B, Pozzi A, McMurray JJV, Jhund PS, Packer M, Desai AS, Lewis EF, Vaduganathan M, Lefkowitz MP, Rouleau JL, Shi VC, Zile MR, Swedberg K, Solomon SD. Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients with Heart Failure and Reduced Ejection Fraction:PARADIGM-HF. Circulation. PMID 31510768 DOI: 10.1161/Circulationaha.119.039920 |
0.46 |
|
| 2019 |
Myhre PL, Claggett B, Ballantyne CM, Selvin E, Røsjø H, Omland T, Solomon SD, Skali H, Shah AM. Association Between Circulating Troponin Concentrations, Left Ventricular Systolic and Diastolic Functions, and Incident Heart Failure in Older Adults. Jama Cardiology. PMID 31483438 DOI: 10.1001/Jamacardio.2019.3113 |
0.412 |
|
| 2019 |
Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, van Veldhuisen DJ, Zannad F, Zile MR, ... ... Claggett B, et al. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. The New England Journal of Medicine. PMID 31475794 DOI: 10.1056/Nejmoa1908655 |
0.456 |
|
| 2019 |
Desai AS, Solomon SD, Shah AM, Claggett BL, Fang JC, Izzo J, McCague K, Abbas CA, Rocha R, Mitchell GF. Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. Jama. 1-10. PMID 31475296 DOI: 10.1001/Jama.2019.12843 |
0.485 |
|
| 2019 |
Chandra A, Seidelmann SB, Claggett BL, Klein BE, Klein R, Shah AM, Solomon SD. The association of retinal vessel calibres with heart failure and long-term alterations in cardiac structure and function: the Atherosclerosis Risk in Communities (ARIC) Study. European Journal of Heart Failure. PMID 31373139 DOI: 10.1002/Ejhf.1564 |
0.39 |
|
| 2019 |
Myhre PL, Vaduganathan M, Claggett BL, Lam CSP, Desai AS, Anand IS, Sweitzer NK, Fang JC, O'Meara E, Shah SJ, Shah AM, Lewis EF, Rouleau J, Pitt B, Solomon SD. Application of the H FPEF score to a global clinical trial of patients with heart failure with preserved ejection fraction: the TOPCAT trial. European Journal of Heart Failure. PMID 31332920 DOI: 10.1002/Ejhf.1542 |
0.426 |
|
| 2019 |
Minamisawa M, Seidelmann SB, Claggett B, Hegde SM, Shah AM, Desai AS, Lewis EF, Shah SJ, Sweitzer NK, Fang JC, Anand IS, O'Meara E, Rouleau JL, Pitt B, Solomon SD. Impact of Malnutrition Using Geriatric Nutritional Risk Index in Heart Failure With Preserved Ejection Fraction. Jacc. Heart Failure. PMID 31302049 DOI: 10.1016/J.Jchf.2019.04.020 |
0.465 |
|
| 2019 |
Chandra A, Vaduganathan M, Lewis EF, Claggett BL, Rizkala AR, Wang W, Lefkowitz MP, Shi VC, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, et al. Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. Jacc. Heart Failure. PMID 31302043 DOI: 10.1016/J.Jchf.2019.05.015 |
0.417 |
|
| 2019 |
Selvaraj S, Claggett B, Shah SJ, Anand IS, Rouleau JL, Desai AS, Lewis EF, Vaduganathan M, Wang SY, Pitt B, Sweitzer NK, Pfeffer MA, Solomon SD. Utility of the Cardiovascular Physical Examination and Impact of Spironolactone in Heart Failure With Preserved Ejection Fraction. Circulation. Heart Failure. 12: e006125. PMID 31220936 DOI: 10.1161/Circheartfailure.119.006125 |
0.424 |
|
| 2019 |
Causland FRM, Claggett B, Sabbisetti VS, Jarolim P, Waikar SS. Hypertonic Mannitol for the Prevention of Intradialytic Hypotension: A Randomized Controlled Trial American Journal of Kidney Diseases. 74: 483-490. PMID 31040088 DOI: 10.1053/J.Ajkd.2019.03.415 |
0.362 |
|
| 2019 |
Kytömaa S, Hegde S, Claggett B, Udell JA, Rosamond W, Temte J, Nichol K, Wright JD, Solomon SD, Vardeny O. Association of Influenza-like Illness Activity With Hospitalizations for Heart Failure: The Atherosclerosis Risk in Communities Study. Jama Cardiology. PMID 30916717 DOI: 10.1001/Jamacardio.2019.0549 |
0.397 |
|
| 2019 |
Minamisawa M, Claggett B, Adams D, Kristen AV, Merlini G, Slama MS, Dispenzieri A, Shah AM, Falk RH, Karsten V, Sweetser MT, Chen J, Riese R, Vest J, Solomon SD. Association of Patisiran, an RNA Interference Therapeutic, With Regional Left Ventricular Myocardial Strain in Hereditary Transthyretin Amyloidosis: The APOLLO Study. Jama Cardiology. PMID 30878017 DOI: 10.1001/Jamacardio.2019.0849 |
0.327 |
|
| 2019 |
Claggett B, Uno H, Wei LJ. Unifying Design and Analysis for Superiority and Noninferiority Trials With Appropriate End Point. Jama Surgery. PMID 30785628 DOI: 10.1001/Jamasurg.2018.5852 |
0.48 |
|
| 2019 |
Vardeny O, Claggett B, Kachadourian J, Desai AS, Packer M, Rouleau J, Zile MR, Swedberg K, Lefkowitz M, Shi V, McMurray JJV, Solomon SD. Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial. European Journal of Heart Failure. PMID 30741494 DOI: 10.1002/Ejhf.1402 |
0.443 |
|
| 2019 |
Claggett B, Pocock S, Wei LJ, Pfeffer MA, McMurray JJV, Solomon SD. Response by Claggett et al to Letter Regarding Article, "Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized Clinical Trials". Circulation. 139: 422-423. PMID 30640547 DOI: 10.1161/Circulationaha.118.038478 |
0.479 |
|
| 2019 |
Beldhuis IE, Myhre PL, Claggett B, Damman K, Fang JC, Lewis EF, O'Meara E, Pitt B, Shah SJ, Voors AA, Pfeffer MA, Solomon SD, Desai AS. Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease. Jacc. Heart Failure. 7: 25-32. PMID 30606484 DOI: 10.1016/J.Jchf.2018.10.017 |
0.41 |
|
| 2019 |
Selvaraj S, Seidelmann S, Silvestre OM, Claggett B, Ndumele CE, Cheng S, Yu B, Fernandes-Silva MM, Grove ML, Boerwinkle E, Shah AM, Solomon SD. HFE H63D Polymorphism and the Risk for Systemic Hypertension, Myocardial Remodeling, and Adverse Cardiovascular Events in the ARIC Study. Hypertension (Dallas, Tex. : 1979). 73: 68-74. PMID 30571559 DOI: 10.1161/Hypertensionaha.118.11730 |
0.336 |
|
| 2019 |
Marco CD, Claggett B, Denus SD, Huynh T, Desai AS, Sirois MG, Jarolim P, Solomon SD, Pitt B, Rouleau JL, Pfeffer MA, O'meara E. P6350Impact of diabetes on serum biomarkers in heart failure with preserved ejection fraction: insights from the spironolactone for heart failure with preserved ejection fraction (TOPCAT) trial European Heart Journal. 40. DOI: 10.1093/Eurheartj/Ehz746.0946 |
0.443 |
|
| 2019 |
Brainin P, Mohr GH, Modin D, Claggett B, Silvestre OM, Shah A, Hviid L, Pedersen CT, Kober L, Solomon S, Schou M, Gislason GH, Biering-Sorensen T. P3438Malaria infection and risk of incident heart failure: a nationwide cohort study European Heart Journal. 40. DOI: 10.1093/Eurheartj/Ehz745.0312 |
0.411 |
|
| 2019 |
Gori M, Claggett B, Shah AM, Senni M, Goldenberg I, Kutyifa V, Solomon SD. 4301Diastolic dysfunction is an independent predictor of adverse events in patients with systolic dysfunction. Insights from the MADIT-CRT trial European Heart Journal. 40. DOI: 10.1093/Eurheartj/Ehz745.0146 |
0.377 |
|
| 2019 |
Inciardi RM, Giugliano R, Claggett B, Ruff C, Gupta D, Antman E, Mercuri M, Grosso M, Rutman H, Braunwald E, Solomon S. Prognostic Role Of Left Atrial Dysfunction And Estimation Of Left Ventricular Filling Pressure On Heart Failure And Cardiovascular Death In Non Valvular Atrial Fibrillation: The Engage-Af Timi Echocardiographic Sub-Study Journal of the American College of Cardiology. 73: 1434. DOI: 10.1016/S0735-1097(19)32040-6 |
0.363 |
|
| 2019 |
Myhre PL, Claggett B, Ballantyne C, Selvin E, Rosjo H, Omland T, Solomon S, Skali H, Shah A. SEX AND RACE DIFFERENCES IN CIRCULATING LEVELS OF NATRIURETIC PEPTIDE CONCENTRATIONS AND THE ASSOCIATION WITH INCIDENT HEART FAILURE IN THE COMMUNITY: THE ATHEROSCLEROSIS RISK IN COMMUNITIES STUDY Journal of the American College of Cardiology. 73: 911. DOI: 10.1016/S0735-1097(19)31518-9 |
0.358 |
|
| 2019 |
Shin S, Claggett B, Pfeffer M, Aguilar D, Diaz R, Dickstein K, Gerstein H, Kober L, Lawson F, Lewis E, Maggioni A, McMurray J, Probstfield J, Riddle MC, Tardif JC, et al. Dysglycemia, Ejection Fraction, And The Risk Of Heart Failure Or Cardiovascular Death In Patients With Type 2 Diabetes And A Recent Acute Coronary Syndrome Journal of the American College of Cardiology. 73: 773. DOI: 10.1016/S0735-1097(19)31381-6 |
0.432 |
|
| 2019 |
Selvaraj S, Claggett B, Shah SJ, Ananda I, Rouleau JL, Desai AS, Lewis EF, Pitt B, Sweitzer NK, Pfeffer MA, Solomon SD. Utility Of Baseline And Follow-Up Cardiovascular Physical Exams In Heart Failure With Preserved Ejection Fraction: Topcat Journal of the American College of Cardiology. 73: 712. DOI: 10.1016/S0735-1097(19)31320-8 |
0.441 |
|
| 2019 |
Selvaraj S, Claggett B, Pozzi A, McMurray JJV, Jhund P, Packer M, Desai AS, Lewis EF, Lefkowitz M, Rouleau JL, Shi V, Zile MR, Swedberg K, Solomon SD. Prognostic Implications Of Baseline And Follow-Up Cardiovascular Physical Exams In A Contemporary Trial Of Patients With Heart Failure With Reduced Ejection Fraction: Paradigm-Hf Journal of the American College of Cardiology. 73: 711. DOI: 10.1016/S0735-1097(19)31319-1 |
0.424 |
|
| 2019 |
Desai AS, Solomon SD, Shah AM, Claggett BL, Fang JC, Izzo J, Abbas CA, Rocha RA, Mitchell GF. Effects of Sacubitril-valsartan Compared with Enalapril on Arterial Hemodynamics, Cardiac Remodeling, and Quality of Life in Patients with Heart Failure and Reduced Ejection Fraction Journal of Cardiac Failure. 25: 938. DOI: 10.1016/J.Cardfail.2019.11.006 |
0.43 |
|
| 2019 |
Vasudeva R, Liu J, Claggett B, Chandra A, Coakley L, Melanson F, Stewart GC, Mehra MR, Lewis EF. QuaLVAD Instrument: A New Measure of Quality of Life in Patients with a Left Ventricular Assist Device (LVAD) Journal of Cardiac Failure. 25. DOI: 10.1016/J.Cardfail.2019.07.448 |
0.317 |
|
| 2019 |
John JE, Claggett B, Skali H, Solomon SD, Cunningham JW, Matsushita K, Konety SH, Kitzman DW, Mosley TH, rd DC, Chang PP, Shah AM. CAD is a Risk Factor for Heart Failure with Preserved Ejection Fraction: The ARIC Study Journal of Cardiac Failure. 25. DOI: 10.1016/J.Cardfail.2019.07.266 |
0.359 |
|
| 2019 |
Cunningham JW, Vaduganathan M, Claggett BL, John JE, Zile MR, Desai AS, Lewis EF, Pfeffer MA, Jhund PS, Kober L, Pitt B, Swedberg K, Anand IS, Yusuf S, McMurray JJV, et al. Prior and Incident Myocardial Infarction in HFpEF: A Pooled, Patient-Level Analysis of 3 Contemporary Clinical Trials with 8,916 Patients Journal of Cardiac Failure. 25. DOI: 10.1016/J.Cardfail.2019.07.214 |
0.407 |
|
| 2019 |
Vardeny O, Vaduganathan M, Claggett B, Desai AS, Anand IS, Shah SJ, O'Meara E, Lewis EF, Rouleau J, Pitt B, Pfeffer MA, Solomon SD. Influence of Age on the Efficacy and Safety of Spironolactone in Heart Failure with Preserved Ejection Fraction Journal of Cardiac Failure. 25. DOI: 10.1016/J.Cardfail.2019.07.036 |
0.397 |
|
| 2019 |
Cohen AJ, Teramoto K, John JE, Claggett B, Solomon SD, Ballantyne CM, Selvin E, Shah AM. Mid- to Late-Life Systemic Inflammation and Late-Life Cardiac Structure and Function: The Atherosclerosis Risk in Communities (ARIC) Study Journal of Cardiac Failure. 25: S7. DOI: 10.1016/J.Cardfail.2019.07.025 |
0.366 |
|
| 2018 |
Huynh T, Harty BJ, Claggett B, Fleg JL, McKinlay SM, Anand IS, Lewis EF, Joseph J, Desai AS, Sweitzer NK, EileenO'Meara, Pitt B, Pfeffer MA, Rouleau JL. Comparison of Outcomes in Patients With Diabetes Mellitus Treated With Versus Without Insulin + Heart Failure With Preserved Left Ventricular Ejection Fraction (from the TOPCAT Study). The American Journal of Cardiology. PMID 30612727 DOI: 10.1016/J.Amjcard.2018.11.022 |
0.464 |
|
| 2018 |
Modin D, Jørgensen ME, Gislason G, Jensen JS, Køber L, Claggett B, Hegde SM, Solomon SD, Torp-Pedersen C, Biering-Sørensen T. Influenza Vaccine in Heart Failure: Cumulative Number of Vaccinations, Frequency, Timing, and Survival: A Danish Nationwide Cohort Study. Circulation. PMID 30586760 DOI: 10.1161/Circulationaha.118.036788 |
0.331 |
|
| 2018 |
Mc Causland FR, Claggett B, Burdmann EA, Chertow GM, Cooper ME, Eckardt KU, Ivanovich P, Levey AS, Lewis EF, McGill JB, McMurray JJV, Parfrey P, Parving HH, Remuzzi G, Singh AK, et al. Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation. PMID 30578152 DOI: 10.1053/J.Ajkd.2018.10.006 |
0.343 |
|
| 2018 |
Myhre PL, O'Meara E, Claggett BL, de Denus S, Jarolim P, Anand IS, Beldhuis IE, Fleg JL, Lewis E, Pitt B, Rouleau JL, Solomon SD, Pfeffer MA, Desai AS. Cardiac Troponin I and Risk of Cardiac Events in Patients With Heart Failure and Preserved Ejection Fraction. Circulation. Heart Failure. 11: e005312. PMID 30571192 DOI: 10.1161/Circheartfailure.118.005312 |
0.461 |
|
| 2018 |
Selvaraj S, Claggett B, Shah SJ, Anand I, Rouleau JL, O'Meara E, Desai AS, Lewis EF, Pitt B, Sweitzer NK, Fang JC, Pfeffer MA, Solomon SD. Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction. Circulation. Heart Failure. 11: e005288. PMID 30571191 DOI: 10.1161/Circheartfailure.118.005288 |
0.451 |
|
| 2018 |
Srivastava PK, Claggett BL, Solomon SD, McMurray JJV, Packer M, Zile MR, Desai AS, Rouleau JL, Swedberg K, Fonarow GC. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial. Jama Cardiology. PMID 30484837 DOI: 10.1001/Jamacardio.2018.3957 |
0.454 |
|
| 2018 |
Kasahara S, Sakata Y, Nochioka K, Tay WT, Claggett BL, Abe R, Oikawa T, Sato M, Aoyanagi H, Miura M, Shiroto T, Takahashi J, Sugimura K, Teng TK, Miyata S, et al. The 3A3B score: The simple risk score for heart failure with preserved ejection fraction - A report from the CHART-2 Study. International Journal of Cardiology. PMID 30413304 DOI: 10.1016/J.Ijcard.2018.10.076 |
0.455 |
|
| 2018 |
Januzzi JL, Packer M, Claggett B, Liu J, Shah AM, Zile MR, Pieske B, Voors A, Gandhi PU, Prescott MF, Shi V, Lefkowitz MP, McMurray JJV, Solomon SD. IGFBP7 (Insulin-Like Growth Factor-Binding Protein-7) and Neprilysin Inhibition in Patients With Heart Failure. Circulation. Heart Failure. 11: e005133. PMID 30354399 DOI: 10.1161/Circheartfailure.118.005133 |
0.329 |
|
| 2018 |
Cikes M, Sanchez-Martinez S, Claggett B, Duchateau N, Piella G, Butakoff C, Pouleur AC, Knappe D, Biering-Sørensen T, Kutyifa V, Moss A, Stein K, Solomon SD, Bijnens B. Machine learning-based phenogrouping in heart failure to identify responders to cardiac resynchronization therapy. European Journal of Heart Failure. PMID 30328654 DOI: 10.1002/Ejhf.1333 |
0.393 |
|
| 2018 |
Sanders NA, Supiano MA, Lewis EF, Liu J, Claggett B, Pfeffer MA, Desai AS, Sweitzer NK, Solomon SD, Fang JC. The frailty syndrome and outcomes in the TOPCAT trial. European Journal of Heart Failure. PMID 30225878 DOI: 10.1002/Ejhf.1308 |
0.406 |
|
| 2018 |
Bouabdallaoui N, Claggett B, Zile MR, McMurray JJV, O'Meara E, Packer M, Prescott MF, Swedberg K, Solomon SD, Rouleau JL. Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial. European Journal of Heart Failure. 20: 1701-1709. PMID 30204280 DOI: 10.1002/Ejhf.1301 |
0.468 |
|
| 2018 |
Myhre PL, Vaduganathan M, Claggett BL, Anand IS, Sweitzer NK, Fang JC, O'Meara E, Shah SJ, Desai AS, Lewis EF, Rouleau J, Pitt B, Pfeffer MA, Solomon SD. Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical Trial. Jama Cardiology. PMID 30140899 DOI: 10.1001/Jamacardio.2018.2568 |
0.455 |
|
| 2018 |
Nochioka K, Querejeta Roca G, Claggett B, Biering-Sørensen T, Matsushita K, Hung CL, Solomon SD, Kitzman D, Shah AM. Right Ventricular Function, Right Ventricular-Pulmonary Artery Coupling, and Heart Failure Risk in 4 US Communities: The Atherosclerosis Risk in Communities (ARIC) Study. Jama Cardiology. PMID 30140848 DOI: 10.1001/Jamacardio.2018.2454 |
0.413 |
|
| 2018 |
Claggett B, Tian L, McCaw ZR, Takeuchi M, Wei LJ. Sex as a predictor of response to cancer immunotherapy. The Lancet. Oncology. 19: e377. PMID 30102227 DOI: 10.1016/S1470-2045(18)30517-5 |
0.362 |
|
| 2018 |
Claggett B, Tian L, Wei LJ. Meta-analysis to Evaluate High-Dose Therapy Followed by Stem Cell Transplant in Patients With Multiple Myeloma. Jama Oncology. PMID 30098159 DOI: 10.1001/Jamaoncol.2018.3483 |
0.462 |
|
| 2018 |
Claggett B, Tian L, Fu H, Solomon SD, Wei LJ. Quantifying the totality of treatment effect with multiple event-time observations in the presence of a terminal event from a comparative clinical study. Statistics in Medicine. PMID 30047148 DOI: 10.1002/Sim.7907 |
0.563 |
|
| 2018 |
Cikes M, Claggett B, Shah AM, Desai AS, Lewis EF, Shah SJ, Anand IS, O'Meara E, Rouleau JL, Sweitzer NK, Fang JC, Saksena S, Pitt B, Pfeffer MA, Solomon SD. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial. Jacc. Heart Failure. PMID 30007557 DOI: 10.1016/J.Jchf.2018.05.005 |
0.43 |
|
| 2018 |
Akacha M, Binkowitz B, Claggett B, Hung HMJ, Mueller-Velten G, Stockbridge N. Assessing Treatment Effects That Capture Disease Burden in Serious Chronic Diseases. Therapeutic Innovation & Regulatory Science. 2168479018784912. PMID 29954224 DOI: 10.1177/2168479018784912 |
0.362 |
|
| 2018 |
Nadruz W, West E, Sengeløv M, Grove GL, Santos M, Groarke JD, Forman DE, Claggett B, Skali H, Nohria A, Shah AM. Cardiovascular phenotype and prognosis of patients with heart failure induced by cancer therapy. Heart (British Cardiac Society). PMID 29764969 DOI: 10.1136/Heartjnl-2018-313234 |
0.435 |
|
| 2018 |
O'Meara E, Prescott MF, Claggett B, Rouleau JL, Chiang LM, Solomon SD, Packer M, McMurray JJV, Zile MR. Independent Prognostic Value of Serum Soluble ST2 Measurements in Patients With Heart Failure and a Reduced Ejection Fraction in the PARADIGM-HF Trial (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure). Circulation. Heart Failure. 11: e004446. PMID 29748349 DOI: 10.1161/Circheartfailure.117.004446 |
0.477 |
|
| 2018 |
Allen LA, Adler ED, Bayés-Genis A, Brisco-Bacik MA, Chirinos JA, Claggett B, Cook JL, Fang JC, Gustafsson F, Ho CY, Kapur NK, Klewer SE, Kociol RD, Lanfear DE, Vardeny O, et al. When the VEST Does Not Fit: Representations of Trial Results Deviating From Rigorous Data Interpretation. Circulation. Heart Failure. 11: e005116. PMID 29666074 DOI: 10.1161/Circheartfailure.118.005116 |
0.415 |
|
| 2018 |
Lewis EF, Claggett B, Shah AM, Liu J, Shah SJ, Anand I, O'Meara E, Sweitzer NK, Rouleau JL, Fang JC, Desai AS, Retta TM, Solomon SD, Heitner JF, Stamos TD, et al. Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure Trial. Circulation. Heart Failure. 11: e004457. PMID 29664406 DOI: 10.1161/Circheartfailure.117.004457 |
0.468 |
|
| 2018 |
Fernandes-Silva MM, Shah AM, Claggett B, Cheng S, Tanaka H, Silvestre OM, Nadruz W, Borlaug BA, Solomon SD. Adiposity, body composition and ventricular-arterial stiffness in the elderly: the Atherosclerosis Risk in Communities Study. European Journal of Heart Failure. PMID 29663586 DOI: 10.1002/Ejhf.1188 |
0.327 |
|
| 2018 |
Packer M, Claggett B, Lefkowitz MP, McMurray JJV, Rouleau JL, Solomon SD, Zile MR. Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial. The Lancet. Diabetes & Endocrinology. PMID 29661699 DOI: 10.1016/S2213-8587(18)30100-1 |
0.332 |
|
| 2018 |
Damman K, Gori M, Claggett B, Jhund PS, Senni M, Lefkowitz MP, Prescott MF, Shi VC, Rouleau JL, Swedberg K, Zile MR, Packer M, Desai AS, Solomon SD, McMurray JJV. Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure. Jacc. Heart Failure. PMID 29655829 DOI: 10.1016/J.Jchf.2018.02.004 |
0.423 |
|
| 2018 |
Vardeny O, Claggett B, Kachadourian J, Pearson SM, Desai AS, Packer M, Rouleau J, Zile MR, Swedberg K, Lefkowitz M, Shi V, McMurray JJV, Solomon SD. Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure). Circulation. Heart Failure. 11: e004745. PMID 29643067 DOI: 10.1161/Circheartfailure.117.004745 |
0.463 |
|
| 2018 |
Selvaraj S, Bhatt DL, Claggett B, Djoussé L, Shah SJ, Chen J, Imran TF, Qazi S, Sesso HD, Gaziano JM, Schrag D. Lack of Association Between Heart Failure and Incident Cancer. Journal of the American College of Cardiology. 71: 1501-1510. PMID 29622155 DOI: 10.1016/J.Jacc.2018.01.069 |
0.417 |
|
| 2018 |
Uno H, Claggett B, Tian L, Fu H, Huang B, Kim DH, Wei LJ. Adding A New Analytical Procedure With Clinical Interpretation in the Tool Box of Survival Analysis. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 29617717 DOI: 10.1093/Annonc/Mdy109 |
0.451 |
|
| 2018 |
Chandra A, Lewis EF, Claggett BL, Desai AS, Packer M, Zile MR, Swedberg K, Rouleau JL, Shi VC, Lefkowitz MP, Katova T, McMurray JJV, Solomon SD. Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial. Jama Cardiology. PMID 29617523 DOI: 10.1001/Jamacardio.2018.0398 |
0.447 |
|
| 2018 |
Proplesch M, Merz AA, Claggett BL, Lewis EF, Dwyer KH, Crousillat DR, Lau ES, Silverman MB, Peck J, Rivero J, Cheng S, Platz E. Right atrial structure and function in patients with hypertension and with chronic heart failure. Echocardiography (Mount Kisco, N.Y.). PMID 29600555 DOI: 10.1111/Echo.13876 |
0.397 |
|
| 2018 |
Claggett B, Pocock S, Wei LJ, Pfeffer MA, McMurray JJV, Solomon SD. Comparison of Time-to-First Event and Recurrent Event Methods in Randomized Clinical Trials. Circulation. PMID 29588314 DOI: 10.1161/Circulationaha.117.033065 |
0.3 |
|
| 2018 |
Desai AS, Liu J, Pfeffer MA, Claggett B, Fleg J, Lewis EF, McKinlay S, O'Meara E, Shah SJ, Sweitzer NK, Solomon S, Pitt B. Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes during Spironolactone Treatment of Heart Failure with Preserved Ejection Fraction: Analysis of the TOPCAT Trial. Journal of Cardiac Failure. PMID 29572190 DOI: 10.1016/J.Cardfail.2018.03.002 |
0.487 |
|
| 2018 |
Niiranen TJ, Henglin M, Claggett B, Muggeo VMR, McCabe E, Jain M, Vasan RS, Larson MG, Cheng S. Trajectories of Blood Pressure Elevation Preceding Hypertension Onset: An Analysis of the Framingham Heart Study Original Cohort. Jama Cardiology. PMID 29562081 DOI: 10.1001/Jamacardio.2018.0250 |
0.307 |
|
| 2018 |
Zhao L, Tian L, Claggett B, Pfeffer M, Kim DH, Solomon S, Wei LJ. Estimating Treatment Effect With Clinical Interpretation From a Comparative Clinical Trial With an End Point Subject to Competing Risks. Jama Cardiology. PMID 29541747 DOI: 10.1001/Jamacardio.2018.0127 |
0.509 |
|
| 2018 |
Nadruz W, Claggett B, Henglin M, Shah AM, Skali H, Rosamond WD, Folsom AR, Solomon SD, Cheng S. Widening Racial Differences in Risks for Coronary Heart Disease. Circulation. 137: 1195-1197. PMID 29530895 DOI: 10.1161/Circulationaha.117.030564 |
0.335 |
|
| 2018 |
Vaduganathan M, Claggett B, Packer M, McMurray JJV, Rouleau JL, Zile MR, Swedberg K, Solomon SD. Natriuretic Peptides as Biomarkers of Treatment Response in Clinical Trials of Heart Failure Jacc-Heart Failure. 6: 564-569. PMID 29501807 DOI: 10.1016/J.Jchf.2018.02.007 |
0.359 |
|
| 2018 |
Vaduganathan M, Claggett BL, Chatterjee NA, Anand IS, Sweitzer NK, Fang JC, O'Meara E, Shah SJ, Hegde SM, Desai AS, Lewis EF, Rouleau J, Pitt B, Pfeffer MA, Solomon SD. Sudden Death in Heart Failure with Preserved Ejection Fraction: A Competing Risks Analysis from the TOPCAT Trial. Jacc. Heart Failure. PMID 29501806 DOI: 10.1016/J.Jchf.2018.02.014 |
0.441 |
|
| 2018 |
Dwyer KH, Merz AA, Lewis E, Claggett B, Crousillat DR, Lau ES, Silverman MB, Peck J, Rivero J, Cheng S, Platz E. Pulmonary Congestion by Lung Ultrasound in Ambulatory Patients with Heart Failure with Reduced or Preserved Ejection Fraction and Hypertension. Journal of Cardiac Failure. PMID 29499322 DOI: 10.1016/J.Cardfail.2018.02.004 |
0.413 |
|
| 2018 |
Lund LH, Claggett B, Liu J, Lam CS, Jhund PS, Rosano GM, Swedberg K, Yusuf S, Granger CB, Pfeffer MA, McMurray JJV, Solomon SD. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. European Journal of Heart Failure. PMID 29431256 DOI: 10.1002/Ejhf.1149 |
0.434 |
|
| 2018 |
Mogensen UM, Gong J, Jhund PS, Shen L, Køber L, Desai AS, Lefkowitz MP, Packer M, Rouleau JL, Solomon SD, Claggett BL, Swedberg K, Zile MR, Mueller-Velten G, McMurray JJV. Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). European Journal of Heart Failure. PMID 29431251 DOI: 10.1002/Ejhf.1139 |
0.443 |
|
| 2018 |
Vazir A, Claggett B, Cheng S, Skali H, Shah A, Agulair D, Ballantyne CM, Vardeny O, Solomon SD. Association of Resting Heart Rate and Temporal Changes in Heart Rate With Outcomes in Participants of the Atherosclerosis Risk in Communities Study. Jama Cardiology. PMID 29365021 DOI: 10.1001/Jamacardio.2017.4974 |
0.428 |
|
| 2018 |
Wolsk E, Claggett B, Køber L, Pocock S, Yusuf S, Swedberg K, McMurray JJV, Granger CB, Pfeffer MA, Solomon SD. Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure. European Journal of Heart Failure. 20: 504-510. PMID 29193462 DOI: 10.1002/Ejhf.1073 |
0.437 |
|
| 2018 |
Beldhuis IE, Myhre PL, Claggett B, Damman K, Fang JC, Lewis EF, O'Meara E, Pitt B, Shah SJ, Voors AA, Pfeffer MA, Solomon SD, Desai AS. P6508Balance of risk and benefit of spironolactone according to renal function in heart failure patients with preserved ejection fraction European Heart Journal. 39. DOI: 10.1093/Eurheartj/Ehy566.P6508 |
0.43 |
|
| 2018 |
Sanchez-Martinez S, Cikes M, Claggett B, Duchateau N, Piella G, Cheng S, Shah A, Bijnens B, Solomon S. 1105Machine-learning analysis of myocardial deformation patterns to predict incident heart failure or death in the general population European Heart Journal. 39. DOI: 10.1093/Eurheartj/Ehy565.1105 |
0.355 |
|
| 2018 |
Biering-Sorensen T, Shah A, Claggett B, Zile M, Pieske B, Pieske-Kraigher E, Voors A, Shi V, Lefkowitz M, Packer M, McMurray JJV, Solomon S. The Angiotensin Receptor Neprilysin Inhibitor (Arni), Sacubitril/Valsartan, Improves Left Ventricular Myocardial Deformation In Heart Failure With Preserved Ejection Fraction (Paramount Trial) Journal of the American College of Cardiology. 71. DOI: 10.1016/S0735-1097(18)33206-6 |
0.45 |
|
| 2018 |
Vaduganathan M, Claggett B, Packer M, McMurray JJV, Rouleau J, Zile M, Swedberg K, Solomon S. Natriuretic Peptides As Predictive Biomarkers Of Treatment Response In Clinical Trials Of Heart Failure Journal of the American College of Cardiology. 71. DOI: 10.1016/S0735-1097(18)31414-1 |
0.365 |
|
| 2017 |
Thorvaldsen T, Claggett BL, Shah A, Cheng S, Agarwal SK, Wruck LM, Chang PP, Rosamond WD, Lewis EF, Desai AS, Lund LH, Solomon SD. Predicting Risk in Patients Hospitalized for Acute Decompensated Heart Failure and Preserved Ejection Fraction: The Atherosclerosis Risk in Communities Study Heart Failure Community Surveillance. Circulation. Heart Failure. 10. PMID 29242352 DOI: 10.1161/Circheartfailure.117.003992 |
0.438 |
|
| 2017 |
Mc Causland FR, Claggett B, Pfeffer MA, Burdmann EA, Eckardt KU, Levey AS, McMurray JJV, Remuzzi G, Singh AK, Solomon SD, Toto RD, Parfrey P. Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial. American Journal of Nephrology. 46: 488-497. PMID 29241199 DOI: 10.1159/000485326 |
0.307 |
|
| 2017 |
Rossignol P, Claggett B, Liu J, Vardeny O, Pitt B, Zannad F, Solomon S. Spironolactone and resistant hypertension in heart failure with preserved ejection fraction. American Journal of Hypertension. PMID 29228101 DOI: 10.1093/Ajh/Hpx210 |
0.39 |
|
| 2017 |
Angelidou KN, Palumbo P, Lindsey J, Violary A, Archary M, Barlow L, Claggett B, Hughes M, Wei LJ. Defining Study Outcomes That Better Reflect Individual Response to Treatment. The Pediatric Infectious Disease Journal. PMID 29189677 DOI: 10.1097/Inf.0000000000001766 |
0.496 |
|
| 2017 |
Selvaraj S, Claggett B, Shah SJ, Anand I, Rouleau JL, Desai AS, Lewis EF, Pitt B, Sweitzer NK, Pfeffer MA, Solomon SD. Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trial. European Journal of Heart Failure. PMID 29148144 DOI: 10.1002/Ejhf.1060 |
0.421 |
|
| 2017 |
Seferovic JP, Pfeffer MA, Claggett B, Desai AS, de Zeeuw D, Haffner SM, McMurray JJV, Parving HH, Solomon SD, Chaturvedi N. Three-question set from Michigan Neuropathy Screening Instrument adds independent prognostic information on cardiovascular outcomes: analysis of ALTITUDE trial. Diabetologia. PMID 29098323 DOI: 10.1007/S00125-017-4485-Y |
0.304 |
|
| 2017 |
Nadruz W, West E, Sengeløv M, Santos M, Groarke JD, Forman DE, Claggett B, Skali H, Shah AM. Prognostic Value of Cardiopulmonary Exercise Testing in Heart Failure With Reduced, Midrange, and Preserved Ejection Fraction. Journal of the American Heart Association. 6. PMID 29089342 DOI: 10.1161/Jaha.117.006000 |
0.395 |
|
| 2017 |
Bajaj NS, Claggett B, Lewis EF, Desai AS, Fang JC, O'Meara E, Shah SJ, Sweitzer NK, Fleg JL, Pitt B, Rouleau JL, Finn P, Pfeffer MA, Solomon SD. Influence of ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction. European Journal of Heart Failure. PMID 29067754 DOI: 10.1002/Ejhf.1040 |
0.425 |
|
| 2017 |
Wolsk E, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber L, Lawson FC, Lewis EF, Maggioni AP, McMurray JJV, Probstfield JL, Riddle MC, Solomon SD, Tardif JC, Pfeffer MA. Increases in Natriuretic Peptides Precede Heart Failure Hospitalization in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus. Circulation. 136: 1560-1562. PMID 29038210 DOI: 10.1161/Circulationaha.117.029503 |
0.396 |
|
| 2017 |
Vazir A, Claggett B, Pitt B, Anand I, Sweitzer N, Fang J, Fleg J, Rouleau J, Shah S, Pfeffer MA, Solomon SD. Prognostic Importance of Temporal Changes in Resting Heart Rate in Heart Failure and Preserved Ejection Fraction: From the TOPCAT Study. Jacc. Heart Failure. PMID 29032132 DOI: 10.1016/J.Jchf.2017.08.018 |
0.468 |
|
| 2017 |
Pak K, Uno H, Kim DH, Tian L, Kane RC, Takeuchi M, Fu H, Claggett B, Wei LJ. Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio. Jama Oncology. PMID 28975263 DOI: 10.1001/Jamaoncol.2017.2797 |
0.508 |
|
| 2017 |
Platz E, Jhund PS, Claggett BL, Pfeffer MA, Swedberg K, Granger CB, Yusuf S, Solomon SD, McMurray JJ. Prevalence and prognostic importance of precipitating factors leading to heart failure hospitalization: recurrent hospitalizations and mortality. European Journal of Heart Failure. PMID 28872259 DOI: 10.1002/Ejhf.901 |
0.375 |
|
| 2017 |
Biering-Sørensen T, Querejeta Roca G, Hegde SM, Shah AM, Claggett B, Mosley TH, Butler KR, Solomon SD. Left ventricular ejection time is an independent predictor of incident heart failure in a community-based cohort. European Journal of Heart Failure. PMID 28872225 DOI: 10.1002/Ejhf.928 |
0.415 |
|
| 2017 |
Lewis EF, Claggett BL, McMurray JJV, Packer M, Lefkowitz MP, Rouleau JL, Liu J, Shi VC, Zile MR, Desai AS, Solomon SD, Swedberg K. Health-Related Quality of Life Outcomes in PARADIGM-HF. Circulation. Heart Failure. 10. PMID 28784687 DOI: 10.1161/Circheartfailure.116.003430 |
0.422 |
|
| 2017 |
Shen L, Jhund PS, Mogensen UM, Køber L, Claggett B, Rogers JK, McMurray JJV. Re-Examination of the BEST Trial Using Composite Outcomes, Including Emergency Department Visits. Jacc. Heart Failure. 5: 591-599. PMID 28774394 DOI: 10.1016/J.Jchf.2017.04.005 |
0.408 |
|
| 2017 |
Shen L, Jhund PS, Petrie MC, Claggett BL, Barlera S, Cleland JGF, Dargie HJ, Granger CB, Kjekshus J, Køber L, Latini R, Maggioni AP, Packer M, Pitt B, Solomon SD, et al. Declining Risk of Sudden Death in Heart Failure. The New England Journal of Medicine. 377: 41-51. PMID 28679089 DOI: 10.1056/Nejmoa1609758 |
0.461 |
|
| 2017 |
Hegde S, Claggett B, Shah AM, Lewis EF, Anand IS, Shah SJ, Sweitzer NK, Fang JC, Pitt B, Pfeffer MA, Solomon SD. Physical Activity and Prognosis in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial. Circulation. PMID 28637881 DOI: 10.1161/Circulationaha.117.028002 |
0.436 |
|
| 2017 |
Charytan DM, Solomon SD, Ivanovich P, Remuzzi G, Cooper ME, McGill JB, Parving HH, Parfrey P, Singh AK, Burdmann EA, Levey AS, de Zeeuw D, Eckardt KU, McMurray JJV, Claggett B, et al. ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD. American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation. PMID 28599901 DOI: 10.1053/J.Ajkd.2017.04.018 |
0.355 |
|
| 2017 |
Wolsk E, Claggett B, Pfeffer MA, Diaz R, Dickstein K, Gerstein HC, Lawson FC, Lewis EF, Maggioni AP, McMurray JJV, Probstfield JL, Riddle MC, Solomon SD, Tardif JC, Køber L. Role of B-Type Natriuretic Peptide and N-Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus. Journal of the American Heart Association. 6. PMID 28554908 DOI: 10.1161/Jaha.116.004743 |
0.338 |
|
| 2017 |
Abdul-Rahim AH, Perez AC, MacIsaac RL, Jhund PS, Claggett BL, Carson PE, Komajda M, McKelvie RS, Zile MR, Swedberg K, Yusuf S, Pfeffer MA, Solomon SD, Lip GYH, Lees KR, et al. Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials. European Heart Journal. 38: 742-750. PMID 28426886 DOI: 10.1093/Eurheartj/Ehw509 |
0.364 |
|
| 2017 |
Anand IS, Claggett B, Liu J, Shah AM, Rector TS, Shah SJ, Desai AS, O'Meara E, Fleg JL, Pfeffer MA, Pitt B, Solomon SD. Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial. Jacc. Heart Failure. 5: 241-252. PMID 28359411 DOI: 10.1016/J.Jchf.2016.11.015 |
0.348 |
|
| 2017 |
Seidelmann SB, Vardeny O, Claggett B, Yu B, Shah AM, Ballantyne CM, Selvin E, MacRae CA, Boerwinkle E, Solomon SD. An NPPB Promoter Polymorphism Associated With Elevated N-Terminal pro-B-Type Natriuretic Peptide and Lower Blood Pressure, Hypertension, and Mortality. Journal of the American Heart Association. 6. PMID 28341776 DOI: 10.1161/Jaha.116.005257 |
0.347 |
|
| 2017 |
Seferovic JP, Claggett B, Seidelmann SB, Seely EW, Packer M, Zile MR, Rouleau JL, Swedberg K, Lefkowitz M, Shi VC, Desai AS, McMurray JJ, Solomon SD. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. The Lancet. Diabetes & Endocrinology. PMID 28330649 DOI: 10.1016/S2213-8587(17)30087-6 |
0.424 |
|
| 2017 |
Biering-Sørensen T, Shah SJ, Anand I, Sweitzer N, Claggett B, Liu L, Pitt B, Pfeffer MA, Solomon SD, Shah AM. Prognostic importance of left ventricular mechanical dyssynchrony in heart failure with preserved ejection fraction. European Journal of Heart Failure. PMID 28322009 DOI: 10.1002/Ejhf.789 |
0.421 |
|
| 2017 |
Biering-Sørensen T, Knappe D, Pouleur AC, Claggett B, Wang PJ, Moss AJ, Solomon SD, Kutyifa V. Regional Longitudinal Deformation Improves Prediction of Ventricular Tachyarrhythmias in Patients With Heart Failure With Reduced Ejection Fraction: A MADIT-CRT Substudy (Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy). Circulation. Cardiovascular Imaging. 10. PMID 28003221 DOI: 10.1161/Circimaging.116.005096 |
0.404 |
|
| 2017 |
Niihara Y, Razon R, Majumdar S, Claggett B, Onyekwere OC, Ikeda A, Singleton T, Wood AK, Singh R, Tran L, Stark CW. Phase 3 Study of L-Glutamine in Sickle Cell Disease: Analyses of Time to First and Second Crisis and Average Cumulative Recurrent Events Blood. 130: 685-685. DOI: 10.1182/Blood.V130.Suppl_1.685.685 |
0.304 |
|
| 2017 |
Biering-Sorensen T, Shah S, Anand I, Sweitzer N, Claggett B, Pitt B, Pfeffer MA, Solomon SD, Shah AM. P6178Prognostic importance of pulmonary pressure in heart failure with preserved ejection fraction European Heart Journal. 38. DOI: 10.1093/Eurheartj/Ehx493.P6178 |
0.395 |
|
| 2017 |
Bajaj NS, Claggett B, Lewis E, Desai A, Fang J, Omeara E, Shah S, Sweitzer N, Fleg J, Pitt B, Rouleau J, Finn P, Pfeffer M, Solomon S. Influence Of Left Ventricular Ejection Fraction On Cause-Specific Mortality In Heart Failure With Preserved Ejection Fraction: The Topcat Trial Journal of the American College of Cardiology. 69: 884. DOI: 10.1016/S0735-1097(17)34273-0 |
0.471 |
|
| 2017 |
Hasegawa T, Claggett B, Tian L, Solomon SD, Pfeffer MA, Wei L. The Myth of Making Inferences for an Overall Treatment Efficacy with Data from Multiple Comparative Studies Via Meta-Analysis Statistics in Biosciences. 9: 284-297. DOI: 10.1007/S12561-016-9179-3 |
0.503 |
|
| 2016 |
Silvestre OM, Gonçalves A, Nadruz W, Claggett B, Couper D, Eckfeldt JH, Pankow JS, Anker SD, Solomon SD. Ferritin levels and risk of heart failure-the Atherosclerosis Risk in Communities Study. European Journal of Heart Failure. PMID 27976478 DOI: 10.1002/Ejhf.701 |
0.384 |
|
| 2016 |
Shah AM, Claggett B, Kitzman D, Biering-Sørensen T, Jensen JS, Cheng S, Matsushita K, Konety SH, Folsom AR, Mosley TH, Wright J, Heiss G, Solomon SD. Contemporary Assessment of Left Ventricular Diastolic Function in Older Adults: The Atherosclerosis Risk in Communities Study. Circulation. PMID 27927714 DOI: 10.1161/Circulationaha.116.024825 |
0.357 |
|
| 2016 |
Zile MR, Claggett BL, Prescott MF, McMurray JJ, Packer M, Rouleau JL, Swedberg K, Desai AS, Gong J, Shi VC, Solomon SD. Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure. Journal of the American College of Cardiology. 68: 2425-2436. PMID 27908347 DOI: 10.1016/J.Jacc.2016.09.931 |
0.383 |
|
| 2016 |
Nadruz W, Claggett BL, McMurray JJ, Packer M, Zile MR, Rouleau JL, Desai AS, Swedberg K, Lefkowitz M, Shi VC, Prescott MF, Solomon SD. Impact of Body Mass Index on the Accuracy of N-Terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide for Predicting Outcomes in Patients With Chronic Heart Failure and Reduced Ejection Fraction: Insights From the PARADIGM-HF Study (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial). Circulation. 134: 1785-1787. PMID 27895026 DOI: 10.1161/Circulationaha.116.024976 |
0.422 |
|
| 2016 |
Shah AM, Claggett B, Loehr LR, Chang PP, Matsushita K, Kitzman D, Konety SH, Kucharska-Newton A, Sueta CA, Mosley TH, Wright JD, Coresh J, Heiss G, Folsom AR, Solomon SD. Heart Failure Stages Among Older Adults in the Community: The Atherosclerosis Risk in Communities Study. Circulation. PMID 27881564 DOI: 10.1161/Circulationaha.116.023361 |
0.382 |
|
| 2016 |
Rossignol P, Girerd N, Bakris G, Vardeny O, Claggett B, McMurray JJ, Swedberg K, Krum H, van Veldhuisen DJ, Shi H, Spanyers S, Vincent J, Fay R, Lamiral Z, Solomon SD, et al. Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia. European Journal of Heart Failure. PMID 27868385 DOI: 10.1002/Ejhf.688 |
0.459 |
|
| 2016 |
Desai AS, Vardeny O, Claggett B, McMurray JJ, Packer M, Swedberg K, Rouleau JL, Zile MR, Lefkowitz M, Shi V, Solomon SD. Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial. Jama Cardiology. PMID 27842179 DOI: 10.1001/Jamacardio.2016.4733 |
0.442 |
|
| 2016 |
Seidelmann SB, Claggett B, Bravo PE, Gupta A, Farhad H, Klein BE, Klein R, Di Carli MF, Solomon SD. Retinal Vessel Calibers in Predicting Long-term Cardiovascular Outcomes: The Atherosclerosis Risk in Communities Study. Circulation. PMID 27682886 DOI: 10.1161/Circulationaha.116.023425 |
0.323 |
|
| 2016 |
Mc Causland FR, Claggett B, Burdmann EA, Eckardt KU, Kewalramani R, Levey AS, McMurray JJ, Parfrey P, Remuzzi G, Singh AK, Solomon SD, Toto RD, Pfeffer MA. C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation. PMID 27646425 DOI: 10.1053/J.Ajkd.2016.07.022 |
0.312 |
|
| 2016 |
Nadruz W, Claggett B, Gonçalves A, Querejeta-Roca G, Fernandes-Silva MM, Shah AM, Cheng S, Tanaka H, Heiss G, Kitzman DW, Solomon SD. Smoking and Cardiac Structure and Function in the Elderly: The ARIC Study (Atherosclerosis Risk in Communities). Circulation. Cardiovascular Imaging. 9: e004950. PMID 27625349 DOI: 10.1161/Circimaging.116.004950 |
0.33 |
|
| 2016 |
Gaziano TA, Fonarow GC, Claggett B, Chan WW, Deschaseaux-Voinet C, Turner SJ, Rouleau JL, Zile MR, McMurray JJ, Solomon SD. Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction. Jama Cardiology. PMID 27438344 DOI: 10.1001/Jamacardio.2016.1747 |
0.421 |
|
| 2016 |
Desai AS, Claggett BL, Packer M, Zile MR, Rouleau JL, Swedberg K, Shi V, Lefkowitz M, Starling R, Teerlink J, McMurray JJ, Solomon SD. Influence of Sacubitril/Valsartan (LCZ696) on 30-Day Readmission After Heart Failure Hospitalization. Journal of the American College of Cardiology. 68: 241-8. PMID 27417000 DOI: 10.1016/J.Jacc.2016.04.047 |
0.381 |
|
| 2016 |
Solomon SD, Claggett B, Packer M, Desai A, Zile MR, Swedberg K, Rouleau J, Shi V, Lefkowitz M, McMurray JJ. Efficacy of Sacubitril/Valsartan Relative to a Prior Decompensation: The PARADIGM-HF Trial. Jacc. Heart Failure. PMID 27395349 DOI: 10.1016/J.Jchf.2016.05.002 |
0.33 |
|
| 2016 |
Solomon SD, Claggett B, McMurray JJ, Hernandez AF, Fonarow GC. Combined neprilysin and renin-angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis. European Journal of Heart Failure. PMID 27364182 DOI: 10.1002/Ejhf.603 |
0.443 |
|
| 2016 |
Desai AS, Solomon S, Claggett B, McMurray JJ, Rouleau J, Swedberg K, Zile M, Lefkowitz M, Shi V, Packer M. Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial. Circulation. Heart Failure. 9. PMID 27296397 DOI: 10.1161/Circheartfailure.115.002735 |
0.403 |
|
| 2016 |
Vardeny O, Claggett B, Packer M, Zile MR, Rouleau J, Swedberg K, Teerlink JR, Desai AS, Lefkowitz M, Shi V, McMurray JJ, Solomon SD. Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. European Journal of Heart Failure. PMID 27283779 DOI: 10.1002/Ejhf.580 |
0.353 |
|
| 2016 |
Gupta DK, Giugliano RP, Ruff CT, Claggett B, Murphy S, Antman E, Mercuri MF, Braunwald E, Solomon SD. The Prognostic Significance of Cardiac Structure and Function in Atrial Fibrillation: The ENGAGE AF-TIMI 48 Echocardiographic Substudy. Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography. PMID 27106009 DOI: 10.1016/J.Echo.2016.03.004 |
0.314 |
|
| 2016 |
Hegde SM, Gonçalves A, Claggett B, Evenson KR, Cheng S, Shah AM, Folsom AR, Solomon SD. Cardiac structure and function and leisure-time physical activity in the elderly: The Atherosclerosis Risk in Communities Study. European Heart Journal. PMID 27071820 DOI: 10.1093/Eurheartj/Ehw121 |
0.339 |
|
| 2016 |
Santos AB, Roca GQ, Claggett B, Sweitzer NK, Shah SJ, Anand IS, Fang JC, Zile MR, Pitt B, Solomon SD, Shah AM. Prognostic Relevance of Left Atrial Dysfunction in Heart Failure With Preserved Ejection Fraction. Circulation. Heart Failure. 9. PMID 27056882 DOI: 10.1161/Circheartfailure.115.002763 |
0.452 |
|
| 2016 |
Nadruz W, Gonçalves A, Claggett B, Querejeta Roca G, Shah AM, Cheng S, Heiss G, Ballantyne CM, Solomon SD. Influence of cigarette smoking on cardiac biomarkers: the Atherosclerosis Risk in Communities (ARIC) Study. European Journal of Heart Failure. PMID 27030444 DOI: 10.1002/Ejhf.511 |
0.301 |
|
| 2016 |
Lewis EF, Kim HY, Claggett B, Spertus J, Heitner JF, Assmann SF, Kenwood CT, Solomon SD, Desai AS, Fang JC, McKinlay SA, Pitt BA, Pfeffer MA. Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial. Circulation. Heart Failure. 9. PMID 26962133 DOI: 10.1161/Circheartfailure.114.001937 |
0.418 |
|
| 2016 |
Solomon SD, Claggett B, Desai AS, Packer M, Zile M, Swedberg K, Rouleau JL, Shi VC, Starling RC, Kozan Ö, Dukat A, Lefkowitz MP, McMurray JJ. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial. Circulation. Heart Failure. 9: e002744. PMID 26915374 DOI: 10.1161/Circheartfailure.115.002744 |
0.474 |
|
| 2016 |
Jarolim P, Claggett BL, Conrad MJ, Carpenter MA, Ivanova A, Bostom AG, Kusek JW, Hunsicker LG, Jacques PF, Gravens-Mueller L, Finn P, Solomon SD, Weiner DE, Levey AS, Pfeffer MA. B-Type Natriuretic Peptide and Cardiac Troponin I Are Associated With Adverse Outcomes in Stable Kidney Transplant Recipients. Transplantation. PMID 26910333 DOI: 10.1097/Tp.0000000000001080 |
0.304 |
|
| 2016 |
Gonçalves A, Hung CL, Claggett B, Nochioka K, Cheng S, Kitzman DW, Shah AM, Solomon SD. Left Atrial Structure and Function Across the Spectrum of Cardiovascular Risk in the Elderly: The Atherosclerosis Risk in Communities Study. Circulation. Cardiovascular Imaging. 9: e004010. PMID 26843540 DOI: 10.1161/Circimaging.115.004010 |
0.338 |
|
| 2016 |
Zile MR, Jhund PS, Baicu CF, Claggett BL, Pieske B, Voors AA, Prescott MF, Shi V, Lefkowitz M, McMurray JJ, Solomon SD. Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study. Circulation. Heart Failure. 9. PMID 26754625 DOI: 10.1161/Circheartfailure.115.002551 |
0.43 |
|
| 2016 |
Vardeny O, Claggett B, Udell JA, Packer M, Zile M, Rouleau J, Swedberg K, Desai AS, Lefkowitz M, Shi V, McMurray JJ, Solomon SD. Influenza Vaccination in Patients With Chronic Heart Failure: The PARADIGM-HF Trial. Jacc. Heart Failure. 4: 152-8. PMID 26746371 DOI: 10.1016/J.Jchf.2015.10.012 |
0.381 |
|
| 2016 |
Zile MR, Jhund PS, Baicu CF, Claggett BL, Pieske B, Voors AA, Prescott MF, Shi V, Lefkowitz M, McMurray JJV, Solomon SD. Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure with a Preserved Ejection Fraction: Data from the Prospective Comparison of ARNI with ARB on Management of Heart Failure with Preserved Ejection Fraction Study Circulation: Heart Failure. 9. DOI: 10.1161/CIRCHEARTFAILURE.115.002551 |
0.315 |
|
| 2016 |
Biering-Sorensen T, Shah S, Ananda I, Sweitzer N, Claggett B, Pitt B, Pfeffer M, Solomon S, Shah A. Prognostic Importance Of Left Ventricular Mechanical Dyssynchrony In Heart Failure With Preserved Ejection Fraction Journal of the American College of Cardiology. 67: 1484. DOI: 10.1016/S0735-1097(16)31485-1 |
0.419 |
|
| 2016 |
Silvestre OM, Junior WN, Roca GQ, Claggett B, London S, Loehr L, Solomon S, Shah A. RAPID DECLINE IN LUNG FUNCTION AND INCIDENT HEART FAILURE: THE ATHEROSCLEROSIS RISK IN COMMUNITIES STUDY Journal of the American College of Cardiology. 67: 1342. DOI: 10.1016/S0735-1097(16)31343-2 |
0.39 |
|
| 2016 |
Junior WN, Claggett B, McMurray J, Packer M, Zile M, Rouleau J, Desai A, Swedberg K, Lefkowitz M, Shi V, Prescott M, Solomon S. Impact Of Body Mass Index On The Accuracy Of Nt-Probnp And Bnp For Predicting Outcomes In Patients With Chronic Heart Failure And Reduced Ejection Fraction: Insights From The Paradigm-Hf Study Journal of the American College of Cardiology. 67: 1326. DOI: 10.1016/S0735-1097(16)31327-4 |
0.416 |
|
| 2016 |
Gaziano TA, Fonarow G, Claggett B, Packer M, Zile M, Swedberg K, Rouleau J, McMurray J, Chan W, Turner S, Deschaseaux C, Solomon S. A Cost-Effectiveness Analysis In The Us Of Lcz696 (Sacubitril/Valsartan) Versus Renin-Angiotensin-Aldosterone System Inhibition For Heart Failure Patients With Reduced Ejection Fraction Journal of the American College of Cardiology. 67: 1302. DOI: 10.1016/S0735-1097(16)31303-1 |
0.399 |
|
| 2016 |
Pandey S, Jhund P, Claggett B, Solomon S, Hagege A, Prescott M, Rouleau J, Swedberg K, Zile M, McMurray J, Packer M. ELEVATED HIGH SENSITIVITY TROPONIN IS ASSOCIATED WITH POORER OUTCOMES IN PATIENTS WITH HEART FAILURE AND REDUCED BY SACUBITRIL/VALSARTAN Canadian Journal of Cardiology. 32: S73. DOI: 10.1016/J.CJCA.2016.07.093 |
0.336 |
|
| 2016 |
Wolsk E, Claggett B, Køber LV, Pocock S, Yusuf S, Swedberg K, McMurray JJV, Granger CB, Pfeffer MA, Solomon SD. Extra-Cardiac Disease Burden Contributes More Than Cardiac Disease Burden to Risk of Cardiovascular Outcomes in Patient with Preserved Ejection Fraction Journal of Cardiac Failure. 22. DOI: 10.1016/J.Cardfail.2016.06.208 |
0.371 |
|
| 2016 |
Vardeny O, Claggett B, Kachadourian J, Pearson SM, Packer M, Zile M, Rouleau J, Swedberg K, McMurray JJV, Solomon SD. Incidence, Predictors, and Outcomes Associated with Hypotensive Episodes among Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial Journal of Cardiac Failure. 22. DOI: 10.1016/J.Cardfail.2016.06.106 |
0.376 |
|
| 2016 |
Lewis EF, Claggett B, McMurray JJV, Packer M, Liu J, Solomon SD, Desai AS, Rouleau JL, Zile M, Shi VC, Lefkowitz MP, Swedberg K. Sacubitril/Valsartan Associated with Lower Declines in Health-Related Quality of Life Compared with Enalapril in Patients with Heart Failure Hospitalization Journal of Cardiac Failure. 22. DOI: 10.1016/J.Cardfail.2016.06.080 |
0.378 |
|
| 2016 |
Lewis EF, Claggett B, Solomon SD, McMurray JJV, Swedberg K, Desai AS, Rouleau JL, Zile M, Shi VC, Lefkowitz MP, Packer M. Racial Differences, Outcomes and Response to Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction: PARADIGM-HF Journal of Cardiac Failure. 22. DOI: 10.1016/J.Cardfail.2016.06.038 |
0.436 |
|
| 2015 |
Li J, Zhao L, Tian L, Cai T, Claggett B, Callegaro A, Dizier B, Spiessens B, Ulloa-Montoya F, Wei LJ. A predictive enrichment procedure to identify potential responders to a new therapy for randomized, comparative controlled clinical studies. Biometrics. PMID 26689167 DOI: 10.1111/Biom.12461 |
0.639 |
|
| 2015 |
Claggett B, Packer M, McMurray JJ, Swedberg K, Rouleau J, Zile MR, Jhund P, Lefkowitz M, Shi V, Solomon SD. Estimating the Long-Term Treatment Benefits of Sacubitril-Valsartan. The New England Journal of Medicine. 373: 2289-90. PMID 26630151 DOI: 10.1056/Nejmc1509753 |
0.417 |
|
| 2015 |
Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, Lawson FC, Ping L, Wei X, Lewis EF, Maggioni AP, McMurray JJ, Probstfield JL, Riddle MC, Solomon SD, et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. The New England Journal of Medicine. 373: 2247-2257. PMID 26630143 DOI: 10.1056/Nejmoa1509225 |
0.309 |
|
| 2015 |
Skali H, Shah A, Gupta, Cheng S, Claggett B, Liu J, Bello N, Aguilar D, Vardeny O, Matsushita K, Selvin E, Solomon S. Response to Letter Regarding Article, “Cardiac Structure and Function Across the Glycemic Spectrum in Elderly Men and Women Free of Prevalent Heart Disease: The Atherosclerosis Risk In the Community Study”. Circ Heart Fail. 8: 1010. PMID 26625500 DOI: 10.1161/Circheartfailure.115.002371 |
0.326 |
|
| 2015 |
Wang N, Hung CL, Shin SH, Claggett B, Skali H, Thune JJ, Køber L, Shah A, McMurray JJ, Pfeffer MA, Solomon SD. Regional cardiac dysfunction and outcome in patients with left ventricular dysfunction, heart failure, or both after myocardial infarction. European Heart Journal. PMID 26530103 DOI: 10.1093/Eurheartj/Ehv558 |
0.414 |
|
| 2015 |
Shah AM, Claggett B, Sweitzer NK, Shah SJ, Deswal A, Anand IS, Fleg JL, Pitt B, Pfeffer MA, Solomon SD. The Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure with Preserved Ejection Fraction and the Impact of Spironolactone. Circulation. Heart Failure. PMID 26475142 DOI: 10.1161/Circheartfailure.115.002249 |
0.43 |
|
| 2015 |
Solomon SD, Claggett B, Lewis EF, Desai A, Anand I, Sweitzer NK, O'Meara E, Shah SJ, McKinlay S, Fleg JL, Sopko G, Pitt B, Pfeffer MA. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. European Heart Journal. PMID 26374849 DOI: 10.1093/Eurheartj/Ehv464 |
0.486 |
|
| 2015 |
Santos AB, Gupta DK, Bello NA, Gori M, Claggett B, Fuchs FD, Shah AM, Coresh J, Sharrett AR, Cheng S, Solomon SD. Prehypertension Is Associated With Abnormalities of Cardiac Structure and Function in the Atherosclerosis Risk in Communities Study. American Journal of Hypertension. PMID 26350299 DOI: 10.1093/Ajh/Hpv156 |
0.327 |
|
| 2015 |
Shah AM, Claggett B, Folsom AR, Lutsey PL, Ballantyne CM, Heiss G, Solomon SD. Ideal Cardiovascular Health During Adult Life and Cardiovascular Structure and Function Among the Elderly. Circulation. PMID 26350059 DOI: 10.1161/Circulationaha.115.017882 |
0.327 |
|
| 2015 |
Roca GQ, Redline S, Claggett B, Bello N, Ballantyne CM, Solomon SD, Shah AM. Sex-Specific Association of Sleep Apnea Severity With Subclinical Myocardial Injury, Ventricular Hypertrophy, and Heart Failure Risk in a Community-Dwelling Cohort: The Atherosclerosis Risk in Communities-Sleep Heart Health Study. Circulation. 132: 1329-37. PMID 26316620 DOI: 10.1161/Circulationaha.115.016985 |
0.343 |
|
| 2015 |
Zhao L, Claggett B, Tian L, Uno H, Pfeffer MA, Solomon SD, Trippa L, Wei LJ. On the restricted mean survival time curve in survival analysis. Biometrics. PMID 26302239 DOI: 10.1111/Biom.12384 |
0.469 |
|
| 2015 |
Lewis EF, Claggett B, Parfrey PS, Burdmann EA, McMurray JJ, Solomon SD, Levey AS, Ivanovich P, Eckardt KU, Kewalramani R, Toto R, Pfeffer MA. Race and ethnicity influences on cardiovascular and renal events in patients with diabetes mellitus. American Heart Journal. 170: 322-9. PMID 26299230 DOI: 10.1016/J.Ahj.2015.05.008 |
0.319 |
|
| 2015 |
Uno H, Tian L, Claggett B, Wei LJ. A versatile test for equality of two survival functions based on weighted differences of Kaplan-Meier curves. Statistics in Medicine. PMID 26194988 DOI: 10.1002/Sim.6591 |
0.462 |
|
| 2015 |
Jhund PS, McMurray JJ, Chaturvedi N, Brunel P, Desai AS, Finn PV, Haffner SM, Solomon SD, Weinrauch LA, Claggett BL, Pfeffer MA. Mortality following a cardiovascular or renal event in patients with type 2 diabetes in the ALTITUDE trial. European Heart Journal. 36: 2463-9. PMID 26188211 DOI: 10.1093/Eurheartj/Ehv295 |
0.319 |
|
| 2015 |
Shah AM, Claggett B, Sweitzer NK, Shah SJ, Anand IS, Liu L, Pitt B, Pfeffer MA, Solomon SD. Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. Circulation. 132: 402-14. PMID 26130119 DOI: 10.1161/Circulationaha.115.015884 |
0.444 |
|
| 2015 |
Uno H, Wittes J, Fu H, Solomon SD, Claggett B, Tian L, Cai T, Pfeffer MA, Evans SR, Wei LJ. Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies. Annals of Internal Medicine. PMID 26054047 DOI: 10.7326/M14-1741 |
0.579 |
|
| 2015 |
Desai AS, McMurray JJ, Packer M, Swedberg K, Rouleau JL, Chen F, Gong J, Rizkala AR, Brahimi A, Claggett B, Finn PV, Hartley LH, Liu J, Lefkowitz M, Shi V, et al. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. European Heart Journal. PMID 26022006 DOI: 10.1093/Eurheartj/Ehv186 |
0.424 |
|
| 2015 |
Bentley-Lewis R, Aguilar D, Riddle MC, Claggett B, Diaz R, Dickstein K, Gerstein HC, Johnston P, Køber LV, Lawson F, Lewis EF, Maggioni AP, McMurray JJ, Ping L, Probstfield JL, et al. Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. American Heart Journal. 169: 631-638.e7. PMID 25965710 DOI: 10.1016/J.Ahj.2015.02.002 |
0.332 |
|
| 2015 |
Charytan DM, Lewis EF, Desai AS, Weinrauch LA, Ivanovich P, Toto RD, Claggett B, Liu J, Hartley LH, Finn P, Singh AK, Levey AS, Pfeffer MA, McMurray JJ, Solomon SD. Cause of Death in Patients With Diabetic CKD Enrolled in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation. PMID 25935581 DOI: 10.1053/J.Ajkd.2015.02.324 |
0.323 |
|
| 2015 |
Jhund PS, Anand IS, Komajda M, Claggett BL, McKelvie RS, Zile MR, Carson PE, McMurray JJ. Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-Preserve study. European Journal of Heart Failure. 17: 809-17. PMID 25921853 DOI: 10.1002/Ejhf.274 |
0.431 |
|
| 2015 |
Theilade S, Claggett B, Hansen TW, Skali H, Lewis EF, Solomon SD, Parving HH, Pfeffer M, McMurray JJ, Rossing P. Pulse pressure is not an independent predictor of outcome in type 2 diabetes patients with chronic kidney disease and anemia-the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT). Journal of Human Hypertension. PMID 25810068 DOI: 10.1038/Jhh.2015.22 |
0.387 |
|
| 2015 |
Skali H, Shah A, Gupta DK, Cheng S, Claggett B, Liu J, Bello N, Aguilar D, Vardeny O, Matsushita K, Selvin E, Solomon S. Cardiac structure and function across the glycemic spectrum in elderly men and women free of prevalent heart disease: the atherosclerosis risk in the community study. Circulation. Heart Failure. 8: 448-54. PMID 25759458 DOI: 10.1161/Circheartfailure.114.001990 |
0.355 |
|
| 2015 |
Voors AA, Gori M, Liu LC, Claggett B, Zile MR, Pieske B, McMurray JJ, Packer M, Shi V, Lefkowitz MP, Solomon SD. Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure. 17: 510-7. PMID 25657064 DOI: 10.1002/Ejhf.232 |
0.436 |
|
| 2015 |
Lam CS, McEntegart M, Claggett B, Liu J, Skali H, Lewis E, Køber L, Rouleau J, Velazquez E, Califf R, McMurray JJ, Pfeffer M, Solomon S. Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). European Journal of Heart Failure. 17: 301-12. PMID 25655011 DOI: 10.1002/Ejhf.238 |
0.311 |
|
| 2015 |
Gonçalves A, Claggett B, Jhund PS, Rosamond W, Deswal A, Aguilar D, Shah AM, Cheng S, Solomon SD. Alcohol consumption and risk of heart failure: the Atherosclerosis Risk in Communities Study. European Heart Journal. 36: 939-45. PMID 25602025 DOI: 10.1093/Eurheartj/Ehu514 |
0.363 |
|
| 2015 |
Quarta CC, Buxbaum JN, Shah AM, Falk RH, Claggett B, Kitzman DW, Mosley TH, Butler KR, Boerwinkle E, Solomon SD. The amyloidogenic V122I transthyretin variant in elderly black Americans. The New England Journal of Medicine. 372: 21-9. PMID 25551524 DOI: 10.1056/Nejmoa1404852 |
0.373 |
|
| 2015 |
Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Heitner JF, Lewis EF, O'Meara E, Rouleau JL, Probstfield JL, et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation. 131: 34-42. PMID 25406305 DOI: 10.1161/Circulationaha.114.013255 |
0.486 |
|
| 2015 |
Vazir A, Claggett B, Jhund P, Castagno D, Skali H, Yusuf S, Swedberg K, Granger CB, McMurray JJ, Pfeffer MA, Solomon SD. Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program. European Heart Journal. 36: 669-75. PMID 25368202 DOI: 10.1093/Eurheartj/Ehu401 |
0.454 |
|
| 2015 |
Claggett B, Tian L, Castagno D, Wei LJ. Treatment selections using risk-benefit profiles based on data from comparative randomized clinical trials with multiple endpoints. Biostatistics (Oxford, England). 16: 60-72. PMID 25122189 DOI: 10.1093/Biostatistics/Kxu037 |
0.574 |
|
| 2015 |
Lewis EF, Claggett B, Liu J, Boineau R, Desai A, Solomon S, Anand I, Sweitzer N, Rouleau JL, Fang J, Thaik C, O’Meara E, Retta TM, Clausell N, McKinlay S, et al. Black Race Associated With Worse Outcomes In Ambulatory Heart Failure-Preserved Ejection Fraction Patients Journal of the American College of Cardiology. 65. DOI: 10.1016/S0735-1097(15)60837-3 |
0.427 |
|
| 2015 |
Hegde S, Goncalves A, Claggett B, Evenson K, Cheng S, Shah A, Folsom A, Solomon S. RELATIONSHIP OF CARDIAC STRUCTURE AND FUNCTION WITH PHYSICAL ACTIVITY IN AN ELDERLY COHORT: THE ATHEROSCLEROSIS RISK IN COMMUNITIES STUDY Journal of the American College of Cardiology. 65: A291. DOI: 10.1016/S0735-1097(15)60291-1 |
0.302 |
|
| 2015 |
Solomon S, Packer M, Zile M, Swedberg K, Rouleau J, Lefkowitz M, Shi V, Desai A, Claggett B, Starling R, McMurray JJV. The Angiotensin Receptor Neprilysin Inhibitor LCZ696 is Effective Across the Spectrum of Ejection Fraction in Heart Failure With Reduced Ejection Fraction Journal of Cardiac Failure. 21. DOI: 10.1016/J.Cardfail.2015.06.158 |
0.412 |
|
| 2014 |
Desai AS, Claggett B, Pfeffer MA, Bello N, Finn PV, Granger CB, McMurray JJ, Pocock S, Swedberg K, Yusuf S, Solomon SD. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. Circulation. Heart Failure. 7: 895-902. PMID 25326006 DOI: 10.1161/Circheartfailure.114.001567 |
0.429 |
|
| 2014 |
Jhund PS, Claggett BL, Voors AA, Zile MR, Packer M, Pieske BM, Kraigher-Krainer E, Shah AM, Prescott MF, Shi V, Lefkowitz M, McMurray JJ, Solomon SD. Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696. Circulation. Heart Failure. 7: 953-9. PMID 25277997 DOI: 10.1161/Circheartfailure.114.001427 |
0.454 |
|
| 2014 |
Shah AM, Kraigher-Krainer E, Gupta DK, Santos A, Claggett B, Pieske B, Zile MR, Voors AA, Lefkowitz MP, Packer M, McMurray JJ, Solomon SD. Reply: does speckle tracking really improve diagnosis and risk stratification in patients with HF with normal EF? Journal of the American College of Cardiology. 64: 1535-6. PMID 25277624 DOI: 10.1016/J.Jacc.2014.04.084 |
0.414 |
|
| 2014 |
Gupta DK, Skali H, Claggett B, Kasabov R, Cheng S, Shah AM, Loehr LR, Heiss G, Nambi V, Aguilar D, Wruck LM, Matsushita K, Folsom AR, Rosamond WD, Solomon SD. Heart failure risk across the spectrum of ankle-brachial index: the ARIC study (Atherosclerosis Risk In Communities). Jacc. Heart Failure. 2: 447-54. PMID 25194293 DOI: 10.1016/J.Jchf.2014.05.008 |
0.426 |
|
| 2014 |
Santos AB, Kraigher-Krainer E, Gupta DK, Claggett B, Zile MR, Pieske B, Voors AA, Lefkowitz M, Bransford T, Shi V, Packer M, McMurray JJ, Shah AM, Solomon SD. Impaired left atrial function in heart failure with preserved ejection fraction. European Journal of Heart Failure. 16: 1096-103. PMID 25138249 DOI: 10.1002/Ejhf.147 |
0.438 |
|
| 2014 |
Shah AM, Claggett B, Sweitzer NK, Shah SJ, Anand IS, O'Meara E, Desai AS, Heitner JF, Li G, Fang J, Rouleau J, Zile MR, Markov V, Ryabov V, Reis G, et al. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial. Circulation. Heart Failure. 7: 740-51. PMID 25122186 DOI: 10.1161/Circheartfailure.114.001583 |
0.465 |
|
| 2014 |
Uno H, Claggett B, Tian L, Inoue E, Gallo P, Miyata T, Schrag D, Takeuchi M, Uyama Y, Zhao L, Skali H, Solomon S, Jacobus S, Hughes M, Packer M, et al. Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 2380-5. PMID 24982461 DOI: 10.1200/Jco.2014.55.2208 |
0.496 |
|
| 2014 |
Gori M, Senni M, Gupta DK, Charytan DM, Kraigher-Krainer E, Pieske B, Claggett B, Shah AM, Santos AB, Zile MR, Voors AA, McMurray JJ, Packer M, Bransford T, Lefkowitz M, et al. Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction. European Heart Journal. 35: 3442-51. PMID 24980489 DOI: 10.1093/Eurheartj/Ehu254 |
0.406 |
|
| 2014 |
Bello NA, Claggett B, Desai AS, McMurray JJ, Granger CB, Yusuf S, Swedberg K, Pfeffer MA, Solomon SD. Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction. Circulation. Heart Failure. 7: 590-5. PMID 24874200 DOI: 10.1161/Circheartfailure.113.001281 |
0.464 |
|
| 2014 |
Vardeny O, Claggett B, Anand I, Rossignol P, Desai AS, Zannad F, Pitt B, Solomon SD. Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist. Circulation. Heart Failure. 7: 573-9. PMID 24812304 DOI: 10.1161/Circheartfailure.114.001104 |
0.429 |
|
| 2014 |
Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, et al. Spironolactone for heart failure with preserved ejection fraction. The New England Journal of Medicine. 370: 1383-92. PMID 24716680 DOI: 10.1056/Nejmoa1313731 |
0.445 |
|
| 2014 |
Jhund PS, Claggett B, Packer M, Zile MR, Voors AA, Pieske B, Lefkowitz M, Shi V, Bransford T, McMurray JJV, Solomon SD. Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial: LCZ696 and blood pressure in HFpEF European Journal of Heart Failure. 16: 671-677. PMID 24692284 DOI: 10.1002/Ejhf.76 |
0.39 |
|
| 2014 |
Querejeta Roca G, Redline S, Punjabi N, Claggett B, Ballantyne CM, Solomon SD, Shah AM. Reply from the authors. American Journal of Respiratory and Critical Care Medicine. 189: 869-70. PMID 24684362 DOI: 10.1164/Rccm.201401-0179Le |
0.348 |
|
| 2014 |
Gupta DK, Skali H, Rivero J, Campbell P, Griffin L, Smith C, Foster C, Claggett B, Glynn RJ, Couper G, Givertz MM, Mehra MR, Carli MD, Solomon SD, Pfeffer MA. Assessment of myocardial viability and left ventricular function in patients supported by a left ventricular assist device. The Journal of Heart and Lung Transplantation : the Official Publication of the International Society For Heart Transplantation. 33: 372-81. PMID 24582837 DOI: 10.1016/J.Healun.2014.01.866 |
0.32 |
|
| 2014 |
Gori M, Lam CS, Gupta DK, Santos AB, Cheng S, Shah AM, Claggett B, Zile MR, Kraigher-Krainer E, Pieske B, Voors AA, Packer M, Bransford T, Lefkowitz M, McMurray JJ, et al. Sex-specific cardiovascular structure and function in heart failure with preserved ejection fraction. European Journal of Heart Failure. 16: 535-42. PMID 24574260 DOI: 10.1002/Ejhf.67 |
0.32 |
|
| 2014 |
Kraigher-Krainer E, Shah AM, Gupta DK, Santos A, Claggett B, Pieske B, Zile MR, Voors AA, Lefkowitz MP, Packer M, McMurray JJ, Solomon SD. Impaired systolic function by strain imaging in heart failure with preserved ejection fraction. Journal of the American College of Cardiology. 63: 447-56. PMID 24184245 DOI: 10.1016/J.Jacc.2013.09.052 |
0.428 |
|
| 2014 |
Santos AB, Kraigher-Krainer E, Bello N, Claggett B, Zile MR, Pieske B, Voors AA, McMurray JJ, Packer M, Bransford T, Lefkowitz M, Shah AM, Solomon SD. Left ventricular dyssynchrony in patients with heart failure and preserved ejection fraction. European Heart Journal. 35: 42-7. PMID 24164863 DOI: 10.1093/Eurheartj/Eht427 |
0.402 |
|
| 2014 |
Jarolim P, Claggett B, Pfeffer M, Ivanova A, Carpenter MA, Bostom A, Kusek J, Hunsicker LG, Gravens-Mueller L, Jacques PF, Finn P, Solomon S, Levey AS. CARDIAC TROPONIN I AND B-TYPE NATRIURETIC PEPTIDE PREDICT CLINICAL OUTCOMES IN STABLE RENAL TRANSPLANT RECIPIENTS Journal of the American College of Cardiology. 63: A1541. DOI: 10.1016/S0735-1097(14)61544-8 |
0.324 |
|
| 2014 |
Cheng S, Claggett B, Correia A, Shah A, Gupta D, Skali H, Heiss G, Folsom A, Coresh J, Solomon S. TEMPORAL TRENDS IN THE POPULATION ATTRIBUTABLE RISK FOR CORONARY HEART DISEASE: ATHEROSCLEROSIS RISK IN COMMUNITIES STUDY Journal of the American College of Cardiology. 63: A1384. DOI: 10.1016/S0735-1097(14)61384-X |
0.356 |
|
| 2014 |
Jhund P, Claggett B, Pfeffer M, Bentley-Lewis R, Brenner BM, Brunel P, Chaturvedi N, Desai A, Haffner S, Parving H, Prescott M, Solomon S, Zeeuw DD, McMurray J. Nt-Probnp And Hstnt Improve Cardiovascular Risk Prediction In Patients With Type 2 Diabetes Mellitus, Chronic Kidney Or Cardiovascular Disease Or Both Journal of the American College of Cardiology. 63. DOI: 10.1016/S0735-1097(14)61279-1 |
0.326 |
|
| 2014 |
Vazir A, Claggett B, Jhund P, Skali H, Castagno D, Swedberg K, Yusuf S, Granger C, McMurray J, Pfeffer M, Solomon S. Resting Heart Rate And Changes In Heart Rate Are Associated With Adverse Outcome In Heart Failure Patients Without Atrial Fibrillation: An Analysis Of The Charm Program Journal of the American College of Cardiology. 63. DOI: 10.1016/S0735-1097(14)60947-5 |
0.457 |
|
| 2014 |
Jhund P, Claggett B, Packer M, Zile M, Voors A, Pieske B, Lefkowitz M, Shi V, Bransford T, McMurray J, Solomon S. The Efficacy Of The Angiotensin Receptor Neprilysin Inhibitor, Lcz696, In Patients With Heart Failure With Preserved Ejection Fraction Is Independent Of Blood Pressure Lowering Journal of the American College of Cardiology. 63. DOI: 10.1016/S0735-1097(14)60812-3 |
0.396 |
|
| 2014 |
Vardeny O, Skali H, Jhund P, Claggett B, Shah AM, Zile MR, Voors AA, Pieske B, Packer M, Lefkowitz MP, Shi V, McMurray JJV, Solomon SD. Influence of Diabetes Mellitus on Cardiac Structure and Function and Response to Therapy with LCZ696 in Heart Failure with Preserved Ejection Fraction Journal of Cardiac Failure. 20. DOI: 10.1016/J.Cardfail.2014.06.114 |
0.393 |
|
| 2013 |
Vardeny O, Gupta DK, Claggett B, Burke S, Shah A, Loehr L, Rasmussen-Torvik L, Selvin E, Chang PP, Aguilar D, Solomon SD. Insulin resistance and incident heart failure the ARIC study (Atherosclerosis Risk in Communities). Jacc. Heart Failure. 1: 531-6. PMID 24455475 DOI: 10.1016/J.Jchf.2013.07.006 |
0.375 |
|
| 2013 |
Querejeta Roca G, Redline S, Punjabi N, Claggett B, Ballantyne CM, Solomon SD, Shah AM. Sleep apnea is associated with subclinical myocardial injury in the community. The ARIC-SHHS study. American Journal of Respiratory and Critical Care Medicine. 188: 1460-5. PMID 24156237 DOI: 10.1164/Rccm.201309-1572Oc |
0.394 |
|
| 2013 |
Zhao L, Tian L, Cai T, Claggett B, Wei LJ. EFFECTIVELY SELECTING A TARGET POPULATION FOR A FUTURE COMPARATIVE STUDY. Journal of the American Statistical Association. 108: 527-539. PMID 24058223 DOI: 10.1080/01621459.2013.770705 |
0.602 |
|
| 2013 |
Vardeny O, Cavallari LH, Claggett B, Desai AS, Anand I, Rossignol P, Zannad F, Pitt B, Solomon SD. Race influences the safety and efficacy of spironolactone in severe heart failure. Circulation. Heart Failure. 6: 970-6. PMID 23940307 DOI: 10.1161/Circheartfailure.113.000530 |
0.401 |
|
| 2013 |
Cheng S, Gupta DK, Claggett B, Sharrett AR, Shah AM, Skali H, Takeuchi M, Ni H, Solomon SD. Differential influence of distinct components of increased blood pressure on cardiovascular outcomes: from the atherosclerosis risk in communities study. Hypertension. 62: 492-8. PMID 23876475 DOI: 10.1161/Hypertensionaha.113.01561 |
0.417 |
|
| 2013 |
Hyett BH, Abougergi MS, Charpentier JP, Kumar NL, Brozovic S, Claggett BL, Travis AC, Saltzman JR. The AIMS65 score compared with the Glasgow-Blatchford score in predicting outcomes in upper GI bleeding. Gastrointestinal Endoscopy. 77: 551-7. PMID 23357496 DOI: 10.1016/J.Gie.2012.11.022 |
0.313 |
|
| 2013 |
Claggett B, Wei LJ, Pfeffer MA. Moving beyond our comfort zone European Heart Journal. 34: 869-871. PMID 23329152 DOI: 10.1093/Eurheartj/Ehs485 |
0.542 |
|
| 2013 |
Desai AS, Claggett B, Pfeffer MA, Bello N, Finn PV, Granger C, Mcmurray JJV, Swedberg K, Yusuf S, Solomon SD. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction European Heart Journal. 34: 1480. DOI: 10.1093/Eurheartj/Eht308.P1480 |
0.325 |
|
| 2013 |
Gupta DK, Skali H, Claggett B, Kasabov R, Shah AM, Loehr L, Heiss G, Nambi V, Aguilar D, Wruck L, Folsom A, Rosamond W, Solomon S. HEART FAILURE RISK ACROSS THE SPECTRUM OF ANKLE–BRACHIAL INDEX: THE ATHEROSCLEROSIS RISK IN COMMUNITIES STUDY Journal of the American College of Cardiology. 61: E2062. DOI: 10.1016/S0735-1097(13)62062-8 |
0.397 |
|
| 2013 |
Vardeny O, Cavallari LH, Claggett B, Anand I, Desai A, Rossignol P, Zannad F, Pitt B, Solomon S. Race Influences The Safety And Efficacy Of Spironolactone In Severe Heart Failure Journal of the American College of Cardiology. 61. DOI: 10.1016/S0735-1097(13)60578-1 |
0.392 |
|
| 2012 |
Castagno D, Petrie MC, Claggett BL, McMurray JJV. Should we SHIFT our thinking about digoxin? Observations on ivabradine and heart rate reduction in heart failure. European Heart Journal. 33: 1137-1141. PMID 22408030 DOI: 10.1093/Eurheartj/Ehs004 |
0.475 |
|
| 2012 |
Vardeny O, Wu D, Claggett B, Desai A, Rossignol P, Zannad F, Pitt B, Solomon SD. Incidence, Predictors and Outcomes Related to Hypo and Hyperkalemia in Severe Heart Failure Patients Treated With an Aldosterone Antagonist Journal of Cardiac Failure. 18. DOI: 10.1016/J.Cardfail.2012.06.193 |
0.427 |
|
| 2011 |
Claggett B, Wei LJ. Analytical issues regarding rosiglitazone meta-analysis. Archives of Internal Medicine. 171: 179-80; author reply. PMID 21263111 DOI: 10.1001/Archinternmed.2010.508 |
0.435 |
|
| 2011 |
Hyett B, Charpentier J, Kumar N, Claggett B, Wu BU, Travis AC, Saltzman JR. Accuracy of Intensive Care Unit Triage and Assessment of Mortality of a Novel Upper Gastrointestinal Bleeding Score (AIMS65) Gastroenterology. 140. DOI: 10.1016/S0016-5085(11)63079-5 |
0.313 |
|
| Show low-probability matches. |